CN103118677A - Uses of benzoate and its derivatives - Google Patents
Uses of benzoate and its derivatives Download PDFInfo
- Publication number
- CN103118677A CN103118677A CN2010800626231A CN201080062623A CN103118677A CN 103118677 A CN103118677 A CN 103118677A CN 2010800626231 A CN2010800626231 A CN 2010800626231A CN 201080062623 A CN201080062623 A CN 201080062623A CN 103118677 A CN103118677 A CN 103118677A
- Authority
- CN
- China
- Prior art keywords
- protective embankment
- dihydroxy
- ester
- benzoic
- acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 52
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 10
- 230000001681 protective effect Effects 0.000 claims description 79
- 150000002148 esters Chemical class 0.000 claims description 65
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 48
- -1 aldehyde radical Chemical class 0.000 claims description 42
- 210000005036 nerve Anatomy 0.000 claims description 37
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 26
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 24
- 229940054066 benzamide antipsychotics Drugs 0.000 claims description 18
- 229940082044 2,3-dihydroxybenzoic acid Drugs 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
- 230000001986 anti-endotoxic effect Effects 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 9
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 claims description 5
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 claims description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 5
- 229960004889 salicylic acid Drugs 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 125000003147 glycosyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 3
- 150000005167 3-hydroxybenzoic acids Chemical class 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims description 3
- GCRHUIVOXJXKHM-UHFFFAOYSA-N octyl 2,3-dihydroxybenzoate Chemical class CCCCCCCCOC(=O)C1=CC=CC(O)=C1O GCRHUIVOXJXKHM-UHFFFAOYSA-N 0.000 claims description 3
- MRBDQKXUSSKGGE-UHFFFAOYSA-N pentyl 2,3-dihydroxybenzoate Chemical class CCCCCOC(=O)C1=CC=CC(O)=C1O MRBDQKXUSSKGGE-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 150000002118 epoxides Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 abstract description 47
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract description 42
- 210000004027 cell Anatomy 0.000 abstract description 40
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 23
- 206010039966 Senile dementia Diseases 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 16
- 210000004556 brain Anatomy 0.000 abstract description 14
- 230000008499 blood brain barrier function Effects 0.000 abstract description 10
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 10
- 150000001558 benzoic acid derivatives Chemical class 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 5
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract description 5
- 230000008929 regeneration Effects 0.000 abstract description 5
- 238000011069 regeneration method Methods 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 4
- 230000004770 neurodegeneration Effects 0.000 abstract description 4
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 104
- MSEMTQOADPAERG-UHFFFAOYSA-N tetradecyl 2,3-dihydroxybenzoate Chemical compound CCCCCCCCCCCCCCOC(=O)C1=CC=CC(O)=C1O MSEMTQOADPAERG-UHFFFAOYSA-N 0.000 description 86
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 55
- 238000006243 chemical reaction Methods 0.000 description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 40
- 239000007787 solid Substances 0.000 description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 36
- 102000015336 Nerve Growth Factor Human genes 0.000 description 36
- 235000021050 feed intake Nutrition 0.000 description 33
- 239000002904 solvent Substances 0.000 description 33
- 238000010189 synthetic method Methods 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- BGHCVCJVXZWKCC-UHFFFAOYSA-N Tetradecane Natural products CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 20
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 20
- 150000005173 2,3-dihydroxybenzoic acids Chemical class 0.000 description 18
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 18
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 210000001320 hippocampus Anatomy 0.000 description 16
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 230000032683 aging Effects 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 230000001537 neural effect Effects 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 102100033639 Acetylcholinesterase Human genes 0.000 description 13
- 108010022752 Acetylcholinesterase Proteins 0.000 description 13
- 238000001035 drying Methods 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 12
- 229940053128 nerve growth factor Drugs 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- 201000006474 Brain Ischemia Diseases 0.000 description 11
- 206010008120 Cerebral ischaemia Diseases 0.000 description 11
- 206010008118 cerebral infarction Diseases 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 10
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 150000001335 aliphatic alkanes Chemical class 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 101000720704 Homo sapiens Neuronal migration protein doublecortin Proteins 0.000 description 8
- 102100025929 Neuronal migration protein doublecortin Human genes 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 7
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000000971 hippocampal effect Effects 0.000 description 7
- 238000012744 immunostaining Methods 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- FODBVCSYJKNBLO-UHFFFAOYSA-N 2,3-dimethoxybenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1OC FODBVCSYJKNBLO-UHFFFAOYSA-N 0.000 description 5
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 5
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 102000006395 Globulins Human genes 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 229950004398 broxuridine Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 239000003900 neurotrophic factor Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000006886 spatial memory Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 229940022698 acetylcholinesterase Drugs 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000012742 biochemical analysis Methods 0.000 description 3
- 230000006931 brain damage Effects 0.000 description 3
- 231100000874 brain damage Toxicity 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012024 dehydrating agents Substances 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000006386 memory function Effects 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- UIAFKZKHHVMJGS-UHFFFAOYSA-N 2,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1O UIAFKZKHHVMJGS-UHFFFAOYSA-N 0.000 description 2
- 150000005174 2,4-dihydroxybenzoic acids Chemical class 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000246500 Gentianella aspera Species 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 2
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 2
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- WOUIKYKNZGCTCD-UHFFFAOYSA-N [O].CCCCCCCCCCCCCC Chemical compound [O].CCCCCCCCCCCCCC WOUIKYKNZGCTCD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N alpha-octadecene Natural products CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- 230000007131 anti Alzheimer effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 150000003935 benzaldehydes Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 210000001947 dentate gyrus Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NLAGNNORBYGNAV-UHFFFAOYSA-N isotriacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCC(C)C NLAGNNORBYGNAV-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 230000007514 neuronal growth Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940038384 octadecane Drugs 0.000 description 2
- CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 210000002763 pyramidal cell Anatomy 0.000 description 2
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960004136 rivastigmine Drugs 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 2
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QKHXKQJMUZVCJM-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;azane Chemical group N.OC(=O)[C@@H](N)CC1=CC=CC=C1 QKHXKQJMUZVCJM-QRPNPIFTSA-N 0.000 description 1
- HUCQPHINKBNKRU-UHFFFAOYSA-N (4-methylphenyl)phosphane Chemical class CC1=CC=C(P)C=C1 HUCQPHINKBNKRU-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 150000005176 2,6-dihydroxybenzoic acids Chemical class 0.000 description 1
- LCULLFKXTQXVNM-UHFFFAOYSA-N 2-[2,3-bis(carboxymethyl)phenyl]acetic acid Chemical class OC(=O)CC1=CC=CC(CC(O)=O)=C1CC(O)=O LCULLFKXTQXVNM-UHFFFAOYSA-N 0.000 description 1
- CQOZJDNCADWEKH-UHFFFAOYSA-N 2-[3,3-bis(2-hydroxyphenyl)propyl]phenol Chemical group OC1=CC=CC=C1CCC(C=1C(=CC=CC=1)O)C1=CC=CC=C1O CQOZJDNCADWEKH-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical class COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- SONNQRNOTIAJDS-GFCCVEGCSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(2R)-2,3-dihydroxypropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC[C@H](CO)O)C=CC=1 SONNQRNOTIAJDS-GFCCVEGCSA-N 0.000 description 1
- FJPUKTJEFOXMJX-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[1-(hydroxymethyl)cyclopropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2(CC2)CO)C=CC=1 FJPUKTJEFOXMJX-UHFFFAOYSA-N 0.000 description 1
- ZUNFPBNHELLPPP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(dimethylamino)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN(C)C)C=CC=1 ZUNFPBNHELLPPP-UHFFFAOYSA-N 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000486199 Gentiana rigescens Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 241001090156 Huperzia serrata Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical class CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- QWKPAKMKAVZXBC-UHFFFAOYSA-N N-phenyl-N-tetradecoxybenzamide Chemical compound C=1C=CC=CC=1N(OCCCCCCCCCCCCCC)C(=O)C1=CC=CC=C1 QWKPAKMKAVZXBC-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000008931 Tadenan Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- JWSIZPAOIFLWKM-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[3-(dimethylamino)-4-hydroxypyrrolidin-1-yl]methanone Chemical compound CN(C)C1CN(CC1O)C(=O)c1cccc(Oc2cc(CN)cc(n2)C(F)(F)F)c1 JWSIZPAOIFLWKM-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 238000011666 aging animal model Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940114055 beta-resorcylic acid Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- AKEUNCKRJATALU-UHFFFAOYSA-N gamma-resorcylic acid Natural products OC(=O)C1=C(O)C=CC=C1O AKEUNCKRJATALU-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930183966 gentiside Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- HOWGUJZVBDQJKV-UHFFFAOYSA-N n-propyl-nonadecane Natural products CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 description 1
- 150000004780 naphthols Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 229940014903 tadenan Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical class ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
- IGNTWNVBGLNYDV-UHFFFAOYSA-N triisopropylphosphine Chemical compound CC(C)P(C(C)C)C(C)C IGNTWNVBGLNYDV-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The uses of benzoate and its derivatives for anti-aging of brain, and for preventing and treating the neurodegenerative diseases such as the senile dementia and the like are provided in the present invention. A series of benzoate and its derivatives are synthesized through a chemical method in the present invention. Proved through cell activity experiments in vitro, the synthesized benzoate and its derivatives have distinguished activities similar to nerve growth factors. Proved through an animal experiment, benzoate and its derivatives do not induce toxic reaction during long term oral or celiac administration, they are able to cross the blood-brain barrier and promote the regeneration of cerebral neuron.
Description
The application of benzoic ether and its derivative
Technical field
The invention belongs to pharmaceutical field, it is related to the application of benzoic ether and its derivative in the nervous system disease and the old disease of Anti-endotoxin activity.
Background technology
With the aging of social population, the illness rate of nerve degenerative diseases, especially senile dementia is significantly raised, it has also become the 4th main cause for causing adult dead.The particularly quickening of China human mortality aging, current patients with Alzheimer disease, including Alzheimer's disease(Alzheimer's disease are said) and blood vessel nature feeble-mindedness, number accounts for the 1/4 of the total case in the world more than 5,000,000.Due to lacking effective prevention and treatment measure so that senile dementia brings serious influence to social stability with development.Therefore, effective new drug of the nerve degenerative diseases such as exploitation prevention and treatment senile dementia is current whole world medical problem in the urgent need to address.Book
The major target class of conventional treatment senile dementia disease drug clinical at present is cholinergic nerve system, such as acetylcholine, acetylcholinesteraseinhibitors inhibitors:Tacrine(Tacrine), rivastigmine(Rivastigmine), huperzine(Huperzine A), donepezil(Donepezil) etc..But these medicines can only partly substitute cholinergic nerve system function, temporarily improve cognitive function, can not prevent and delay the progress of nerve retrograde affection.Moreover, long-term taking curative effect is gradually reduced, there is side effect.Therefore, old and prevention nerve retrograde affection the novel drugs of exploitation Anti-endotoxin activity, it has also become the focus studied at present.
It is to cause the main cause of cognition dysfunction that the nerve cell death and nervous function of brain, which decline,.In recent years research is it was demonstrated that the newborn neuron of adult brain(Nerve regneration)It can replace and repair due to the neuron loss that natural aging or lesion are caused, to safeguarding that the 26S Proteasome Structure and Function of brain plays the effect of key.Nerve growth factor(Nerve growth factor, NGF) it is a kind of biologically active polypeptide to having important regulating and controlling to act in terms of the growth of nerve, development, differentiation and function holding found earliest, it is most important neurotrophic factor.Particularly during the nervous system disease, neurotrophic factor has important protective effect to nerve cell and nerve regneration.Neurotrophic factor can prevent or reduce neural Wei Shrink, neurodegeneration, promote post-traumatic CO2 laser weld.However, it is the protein being made up of more than 100 amino acid;Due to the reason such as molecular weight is big and polarity is strong, it is impossible to be the bottleneck for limiting nerve growth factor clinical practice by blood-brain barrier, do not find more preferable treatment method also in addition to intracerebral operation is directly offerd medicine at present.Therefore, nerve growth factor is found to intend like thing(NGF mimiCS), nerve growth factor reinforcing agent(NGF enhancer) and nerve growth factor primer(NGF inducer) it is considered as the new target drone that research prevents and treats nerve degenerative diseases.
Chinese herbal medicine is the material base of Chinese pharmacology, is the cornucopia of natural activity organic compound.There is the traditional Chinese medical science civilization of thousands of years in China, and vast territory and abundant resources, the genunie medicinal materials for having many preciousnesses, because the utilization of Chinese material medicine resource is more convenient, also just particularly significant to its new composition and new active research.Research shows that Chinese medicine has significant curative effect to senile dementia, wherein foremost is the huperzine of alkaloid one extracted from Huperzia serrata(Huperzine A), it is the medicine of the Anti-alzheimer's disease with independent intellectual property right of institute of materia medica of Chinese Academy of Sciences exploitation.Mainly there is acetylcholine esterase inhibition activity, reduce glutamic acid and induce nerve cell death, the neurotoxicity and antioxidation of anti-beta-amyloyd polypeptide.
Rough gentian, alias:Andrographis paniculata, courage grass.Spring, the excavation of season in autumn two, cleaning, drying.Nature and flavor, it is bitter, tremble with fear.Return liver, courage
Through.Introduced in 2005 editions pharmacopeia, the major function of rough gentian:Heat-clearing and damp-drying drug, purging the liver of pathogenic fire courage fire.For jaundice with damp-heat pathogen, swelling of vulva pruritus vulvae, with, persistent erection, eczema itch, hot eyes, deafness, hypochondriac pain, bitter taste, convulsion.The identification of its biological activity system set up using PC12 cells, obtain more than ten kinds with notable similar Nerve Growth Factor Activity 2 are isolated and purified from the extract of Gentiana rigescens Gmtiana rigescens Franch. drying root and rhizome, 3- dyhydroxyl parabens noval chemical compounds, it is named as gentisides o on this basis, has synthesized a series of benzoic ethers and its derivative(Detailed in Example 1), it is found that benzoic ether and its derivative have the growth promoting function of similar nerve growth factor.Particularly, the ester of 2,3- dihydroxy-benzoic acids 14(Be named as ABG-001) the processing of Ι μ Μ low concentrations, it is shown that it is significant to promote nerve growth effect(Detailed in Example 2-1).So far, not yet there are benzoate compounds that there is the relevant report of similar NGF activity of anti-senile dementia.
The content of the invention
In view of the above-mentioned deficiencies in the prior art, it is an object of the present invention to provide the preparation method and application of benzoic ether and its derivative.The purpose of the present invention is achieved through the following technical solutions:The application of a kind of benzoic ether and its derivative in prevention and treatment nerve degenerative diseases and the old medicine of Anti-endotoxin activity is prepared, the benzoic ether and its derivative have following structure formula:
Wherein, R is carbon number from 1 to 30 straight chain, side chain, saturation and unsaturated alkyl, cycloaliphatic ring or their derivative; 〜R5Separately it is selected from hydrogen, hydroxyl, carboxyl, aldehyde radical, ester group, fluorine, chlorine, bromine, iodine, sulfydryl, amino, amide groups, cyano group, nitro, sulfonic group, trifluoromethyl, acrylic, alkyl, alkoxy, substituted benzyl, substituted-phenyl, aryl, heteroaryl, glycosyl and amino acid residue;X is selected from C (0) 0, OC (0), C (0) NH, NHC (0), C (0), CH2, S standing grain Jie 0.
Further, the R is carbon number from 6 to 22 straight chain, side chain, saturation and unsaturated alkyl, cycloaliphatic ring or their derivative.
Further, the benzoic ether and its derivative are: 2,3- dihydric ethyl benzoates, 2,3- dihydroxy-benzoic acid pentyl esters, 2,3- dihydroxy-benzoic acid monooctyl esters, 2,3- dihydroxy-benzoic acid last of the ten Heavenly stems esters, 2,3- dihydroxy-benzoic acid dodecane esters, 2,3- dihydroxy-benzoic acid tetradecane esters, 2,3- dihydroxy-benzoic acid hexadecane esters, 2,3- dihydroxy-benzoic acid octadecane esters, 2,3- dihydroxy-benzoic acid eicosane esters, 2,3- dihydroxy-benzoic acid docosane esters, 2,3- dihydroxy-benzoic acid melissane esters, 2,6- dihydroxy-benzoic acid tetradecane esters, 2,6- dihydroxy-benzoic acid eicosane esters, 2,4- dihydroxy-benzoic acid tetradecane esters, 3,4- dihydroxy-benzoic acid tetradecane esters, 3, 4,5- trihydroxybenzoic acid tetradecane esters,2 hydroxybenzoic acid tetradecane ester,3- hydroxybenzoic acid tetradecane esters, 2,3- dimethoxybenzoic acid tetradecane esters, 2,3- dimethoxybenzoic acid octadecane esters,2- hydroxy 3-methoxybenzene formic acid tetradecane esters,2- chlorobenzoic acid tetradecane esters, 2,3- dihydroxy-N- myristyl benzamides, 2,3- dihydroxy-N- octyl group benzamides, 2,3- dihydroxy-N- dodecyl benzamides, 2,3- dihydroxy-N- cetyl benzamides, 2,3- dihydroxy-N- octadecyl benzamides, 2,3- dimethoxy-N- myristyl benzamides, 3,4- dihydroxy-N- myristyl benzamides, 3, 4,5- trihydroxy-N- myristyl benzamides, N- (3,4- Dimethoxyphenyls) 14(Alkane) acid amides, N- (3,4-
Dihydroxyphenyl) 14(Wash) acid amides, 1- (3; 4- Dimethoxyphenyls) tetradecane -1- ketone, 1- (3; 4- dihydroxyphenyls) tetradecane -1- ketone, 3- (tetradecyloxyaniline carbonyl) -1; 2- phenyl diacetate, 3- (myristyl formoxyl) -1; 2- phenyl diacetate, 5- (tetradecyloxyaniline carbonyl) benzene -1; 2; 3- triacetates, 5- (myristyl formoxyl) benzene -1; 2; 3- triacetates, 1; the acid esters of 2- phenylene 20,2,3- dihydroxyphenyls 14(Alkane) hydrochlorate, 3- (tetradecane oxygen) benzene -1,2- glycol.
The beneficial effects of the present invention are:(1) 2,3- dyhydroxyl parabens compounds(ABG-001) oral or intraperitoneal administration finds no toxic action, and the compound can enter intracerebral quickly through blood-brain barrier, adjusts cerebral nervous system function;(2) Animal pharmacology experiments result is proved, of the present invention 2,3- dyhydroxyl parabens compounds can promote neuron regeneration, the aging of anti-brain, the neurotoxicity for preventing β starch polypeptides, the reduction acetylcholine esterase active of adult brain, the effect with prevention and treatment senile dementia and Anti-endotoxin activity always.
Brief description of the drawings
Fig. 1 is the dosage dependence figure that compound ABG-001 promotes the elongation of PC12 cellular neurals projection;
Fig. 2 is addition ABG-001, the microphoto of the cellular neural projections of PC 12 after 48 hours, wherein, a is 1% DMSO, is negative control;B is the ng/ml of NGF 40, is positive control;C is ABG-001 (1 μ Μ);
Fig. 3 represents that ABG-001 plays the role of to intend nerve growth factor, wherein,(A) it is the expression figure of hippocampal neural growth factor, (b) is the quantity figure of newborn neuron;
Fig. 4 represents that ABG-001 treatments can promote nerve regneration and migration after cerebral ischemia;
Fig. 5 represents that ABG-001 can be by blood-brain barrier;
Fig. 6 represents that ABG-001 can promote nerve regneration of growing up by blood-brain barrier, wherein,(A) it is the quantity figure of newborn neuron,(B) it is newborn neuron projection length figure,(C) it is the differentiation figure of newborn neuron;
Fig. 7 represents that ABG-001 has the effect of Anti-endotoxin activity always, wherein,(A) it is the quantity figure of newborn neuron,(B), (c) and(D) it is Morris water maze test figures,(e)、 (0th, (g) and(H) it is the oxidative stress biochemical indicator figure of mouse;Fig. 8 represents that ABG-001 has the effect of Anti-endotoxin activity always, wherein,(A) arm number of times is always entered for Y labyrinths,
(b) arm rate is alternately entered for Y labyrinths,(C) and(D) it is the resolving ability figure of novelty;
Fig. 9 is that Α β are damaged and Α β damage Morris water maze test figures after ABG-001 treatments;
Figure 10 represents that ABG-001 treatments can improve Α β infringements(APP/PS1 mouse)Nerve regneration, wherein,(A) it is the quantity figure of newborn neuron,(B) it is the projection length figure of newborn nerve,(C) it is acetylcholinesterase(AChE) activity figure.Embodiment
2,3- dyhydroxyl parabens compounds can cause a high proportion of PC12 cells to occur nervous process elongation phenomenon, show that 2,3- dihydroxy-benzoic acids ester has good similar NGF activity, the value with exploitation anti-senile dementia prophylactic treatment medicine.With 2,3- dihydroxy-benzoic acid ester compounds as primer, a series of benzoate derivatives are designed and synthesized, carries out the research of its external activity extensively, finds the structure-activity relationship of such material.It if the compound with potential more excellent activity and/or more hypotoxicity can be found, and can be used to preventing and treating the nervus retrogressions such as senile dementia and the old disease of Anti-endotoxin activity, will have important practical significance.
Benzoate derivatives of the present invention, the structure of the compound can be represented with formula I:
I
In formula:R be carbon number from 1 to 30 straight chain or side chain or saturation and unsaturated alkyl or cycloaliphatic ring or their derivative, particularly C6〜C22 ;
〜R5Separately it is selected from hydrogen, hydroxyl, carboxyl, aldehyde radical, ester group, fluorine, chlorine, bromine, iodine, sulfydryl, amino, amide groups, cyano group, nitro, sulfonic group, trifluoromethyl, acrylic, alkyl, alkoxy, substituted benzyl, substituted-phenyl, aryl, heteroaryl, glycosyl and amino acid residue;
X is selected from C (0) 0, OC (0), C (0) NH, NHC (0), C (0), CH2, S and 0.
The preparation method of benzoic ether and its derivative of the present invention, is realized by following steps:
1) when X is the preparation method of c (o) o or oc (o) ester type compound:First acid is completely dissolved with alcohol or phenol with solvent, cold to cause 0 °C, stirring is lower to be added dropwise dehydrating agent, is raised again to room temperature reaction 12 days, is tracked and reacted with thin-layer chromatography.After reaction terminates, solvent is steamed, is post-processed, then ester type compound is purified to obtain through silica gel column chromatography.Acid be substituted benzoic acid or carbon number from 1 to 30 straight chain or side chain or saturation and unsaturated alkyl or cycloaliphatic ring or their derivative, particularly C6〜C22Aliphatic acid;Alcohol be carbon number from 1 to 30 straight chain or side chain or saturation and unsaturated alkyl or cycloaliphatic ring or their derivative, particularly C6〜C22Fatty alcohol;Phenol is fortified phenol;Dehydrating agent is the concentrated sulfuric acid, DIC or dicyclohexylcarbodiimide;Solvent is protonic solvent methanol, ethanol or tetrahydrofuran, or non-protonic solvent dichloromethane, chloroform, benzene,toluene,xylene, dimethyl sulfoxide or acetonitrile;The mol ratio of acid and alcohol is 1:1〜1 :20, the sour mol ratio with dehydrating agent is 1:0.2〜1 :3.
2) when X is the preparation method of C (0) NH or NHC (O) amides compound:By acid, amine is dissolved with the dry solvent of hydroxybenzotriazole, and cold to cause 0 °C, the lower Jia Ru Shrink mixture of stirring is reacted at room temperature 25 days.After reaction terminates, solvent evaporated, residue ethyl acetate dissolves, successively with saturated sodium bicarbonate solution, water washing, and anhydrous magnesium sulfate dries , Nong Shrink, then purifies to obtain acid amides through silica gel column chromatography.Acid is substituted benzoic acid or carbon number from 1 to 30 straight or branched, saturated or undersaturated aliphatic acid;Amine be substituted aniline or carbon number from 1 to 30 straight or branched, saturation or undersaturated fatty amine.The mol ratio of acid and amine is 1:1〜1 :The mol ratio of 5, Suan Yu Shrink mixture is 1:1〜1 :5.
3) when X is the preparation method of C (O) ketone compounds:Under inert gas shielding, the magnesium metal of activation is added in absolute ether, the diethyl ether solution of brominated alkanes is added dropwise.Continue the diethyl ether solution of instillation brominated alkanes, back flow reaction 1 hour after grignard reaction starts.Then under inert gas shielding, 0 °C, the grignard reagent prepared is added drop-wise in the diethyl ether solution of aldehyde, is warmed to room temperature reaction 2 hours.Question response is finished, by cold 0 °C of the cause of reaction solution, it is slowly added into 1 mole of every liter of hydrochloric acid solution, with ether extractive reaction liquid, organic phase is successively with 1 mole of every liter of watery hydrochloric acid, saturated sodium bicarbonate solution, saturated common salt water washing, anhydrous magnesium sulfate dries , Nong Shrink, then purifies to obtain alcohol compound through silica gel column chromatography.Inert gas is nitrogen or argon gas;Solvent is absolute ether or tetrahydrofuran;Aldehyde is substituted benzaldehyde;Brominated alkanes are carbon numbers from 1 to 30 straight or branched, saturation or undersaturated brominated alkanes;Reaction temperature can be from -80 degree to 50 degree;The mol ratio of brominated alkanes and magnesium is 1:1〜1 :10;
The mol ratio of brominated alkanes and substituted benzaldehyde is 1:1〜1 :10.
Alcohol compound is completely dissolved with solvent, it is slowly added to oxidant, reaction is finished, Jian Ya Nong Shrink, the dense Shrink liquid of gained is diluted with ethyl acetate, successively with 1 mole of every liter of watery hydrochloric acid, saturated sodium bicarbonate solution, saturated common salt water washing, and anhydrous magnesium sulfate is dried; dense Shrink, then purifies to obtain ketone compounds through silica gel column chromatography.Solvent can be tetrahydrofuran, dichloromethane, acetone, chloroform, dimethyl sulfoxide or acetonitrile;Oxidant can be chromium trioxide, manganese dioxide, dimethyl sulfoxide, periodate or N-methyl morpholine oxide.The mol ratio of alcohol and oxidant is 1:1〜1 :10.
4) when X is the preparation method of 0 ether compound:I.e. under inert gas shielding, phenol is dissolved in dry tetrahydrofuran, stirring is lower to add alcohol, triphenylphosphine, diethyl azodiformate, reacts at room temperature 1 24 hours.After reaction terminates, solvent is removed under reduced pressure.Ethyl acetate dilutes dense Shrink liquid, with deionized water, saturated common salt water washing, and anhydrous magnesium sulfate is dried, and subtracts the dense Shrink organic phases of pressure, and the dense Shrink liquid of gained purifies to obtain ether compound through silica gel column chromatography again.Phenol is fortified phenol, substituted naphthol;Alcohol is carbon number from 1 to 30 straight or branched, saturation or unsaturated fatty alcohol;Azo-reagents can be diethyl azodiformate, azoformic acid dipropyl, diisopropyl azodiformate, tert-butyl azodicarboxylate or azoformic acid dibenzyl ester;Phosphine reagent can be triphenylphosphine, tri isopropyl phosphine, three p-methylphenyl phosphines, triethyl phosphine, tributylphosphine or tricyclohexyl phosphine;Solvent is protonic solvent methanol or ethanol, or non-protonic solvent tetrahydrofuran, dichloromethane, chloroform, benzene,toluene,xylene, dimethyl sulfoxide or acetonitrile;The mol ratio of phenol and alcohol is 1:20, the mol ratio of phenol and Azo-reagents is 1:0.2〜1 :20;The mol ratio of phenol and phosphine reagent is 1:0.2〜1 :20.
The purpose of the present invention is the application of benzoic ether and its derivative in treatment Alzheimer's disease and the old disease medicament of Anti-endotoxin activity is prepared.
The present invention further also provide it is a kind of treat Anti-alzheimer's disease disease and the old pharmaceutical composition of Anti-endotoxin activity, the pharmaceutical composition contains the benzoic ether and its derivative of physiology effective dose() and pharmaceutically acceptable carrier or diluent I.Shown benzoic ether and its derivative(I) the weight ratio in medicine is the % of 0.1 % 90.
Pharmaceutically acceptable carrier described here refers to the conventional pharmaceutical carrier of pharmaceutical field, such as diluent, excipient in this way, filler such as starch, sucrose, microcrystalline cellulose etc.;Adhesive such as starch slurry, hydroxypropylcellulose, gelatin, polyethylene glycol etc.;Wetting agent such as magnesium stearate, superfine silica gel powder, polyethylene glycols etc.;The poly- sorb fat of sorbefacient, lecithin etc., surfactant poloxamer, fatty acid sorbitan, poly- sorb fat etc., it can in addition contain add other assistant agents such as flavouring agent, sweetener etc. in the composition.
Benzoate derivatives of the present invention can be administered in a unit, and method of administration can be enteron aisle and non-bowel, including oral, muscle and subcutaneous.Compound method of administration is alternatively intravenously administrable.Injection includes intravenous injection, intramuscular injection, hypodermic injection and acupoint injection therapy.
The various formulations of the pharmaceutical composition of the present invention can be prepared according to the conventional production process of pharmaceutical field, for example, active component is mixed with one or more carriers, be then made into required formulation.
Form of administration can be solid pharmaceutical preparation, capsule or liquid preparation, including tablet, capsule, dispersible tablet, oral liquid, big transfusion, small pin, freeze-dried powder.
Benzoic ether and its derivative of the present invention have the activity of significant similar nerve growth factor, and the effect with neuroprotection and Anti-endotoxin activity always can be applied in the nerve degenerative diseases such as prevention senile dementia and Anti-endotoxin activity are old.The benzoate compounds of the present invention show significant NGF in the in-vitro screening model PC12 cells of senile dementia
Mimics activity.Using such compound as primer, optimize structure, the new drug development for nerve degenerative diseases such as prevention and treatment senile dementias carries out basic research, will have important practical significance.
Benzoic ether and its derivative of the present invention can be by blood-brain barriers, with dynamical neurotrophic effect.Benzoic ether and its derivative of the present invention have the aging of anti-brain, and prevent and treat the effect of senile dementia.The above below by way of the embodiment and accompanying drawing to such some particular compound preparating example again to the present invention is described in further detail, but this should not be interpreted as to the scope of above-mentioned theme of the invention and be only limitted to following examples, all technologies realized based on the above of the present invention belong to the scope of the present invention.
Embodiment 1
Compound 1-1:2,3- dihydric ethyl benzoates
Will(154 mg, l mmol) 2,3- dihydroxy-benzoic acids, 10 ml ethanol are placed in 25 ml round-bottomed flasks, cold to cause 0 °C, are added dropwise 23 and are dripped the concentrated sulfuric acid, the h of return stirring 24.Use thin-layer chromatography(Solvent:Just oneself washes/ethyl acetate, 5/1, V/V) tracking reaction, after reaction stops, ethanol is steamed, the mg of crude product 390, silica gel column chromatography is obtained(Solvent:Just oneself washes/ethyl acetate, 5/1, V/V), obtain the mg of white solid 180.1H NMR (500 MHz, CDC13) δ:11.00 (s, 1H, benzene 2-OH), 7.38 (dd, 1 Η, /=1.5,8.0 Hz, benzene H-6), 7.12 (dd, 1H, /=1.0,7.5 Hz, benzene H-4), 6.80 (t, 1H, J=8.0 Hz, benzene H-5), 5.66 (s, 1H, benzene 3-OH), 4.41 (q, 2H, the Hz of J=7.0), 1.42 (t, 3H, J=7.0 Hz); HRMS: m/z [M+H]+ calcd for C9Hu04 +: 183.0652, found: 183.0639.
Compound I -2:2,3- dihydroxy-benzoic acid pentyl esters
Synthetic method with compound 1-1, reaction feed intake for:(154 mg, l mmol) 2,3- dihydroxy-benzoic acids, 10 ml amylalcohols, obtain white solid 170 mg o 1H NMR (500 MHz, CDC13) δ:11.00 (s, 1H), 7.38 (dd, 1H, J=1.5,8.0 Hz), 7.12 (dd, 1H, /=1.0,8.0 Hz), 6.80 (t, 1H, /=8.0 Hz), 5.65 (s, 1H), 4.41 (t, 2H, the Hz of /=7.0), 1.78 (m, 2H), 1.33 1.38 (m, 4H), 0.90 (t, 3H, /=7.0 Hz);13C NMR (125 MHz, CDC13) δ:170.4,148.9,145.1,120.5,119.7,119.1,112.7,65.7,28.2,28.1,22.3,13.9 ppm; IR (KBr) v:3458,2931,2865,1674,1469,1309,1268,1067,754 cm1; HRMS: m/z [M+H]+ calcd for C12H1704 +: 225.1121 , found: 225.1104.
Compound I -3:2,3- dihydroxy-benzoic acid monooctyl esters
Synthetic method with compound 1-1, reaction feed intake for:(154 mg, l mmol) 2,3- dihydroxy-benzoic acids, 10 ml octanols, obtain white solid 128 mg o 1H NMR (500 MHz, CDC13) δ:11.01 (s, 1 Η), 7.38 (dd, 1 Η, /=1.5,8.0 Hz), 7.10 (dd, 1H, /=1.0,8.0 Hz), 6.80 (t, 1H, the Hz of /=8.0), 5.64 (s, 1H), 4.35 (t, 2H, /=7.0 Hz), 1.78 (m, 2H), 1.44 (m, 2H), 1.26 1.38 (m, 8H), 0.89 (t, 3H, /=7.0 Hz); HRMS: m/z [M+H]+ calcd for C15H2304 +: 267.1591 , found: 267.1590.
Compound I -4:2,3- dihydroxy-benzoic acid last of the ten Heavenly stems esters
Will(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(316 mg, 2 mmol) Decanol, 10 ml tetrahydrofurans are placed in 25 ml round-bottomed flasks, cold to cause 0 °C, are added(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 24 h are stirred at room temperature.Use thin-layer chromatography(Solvent:Just oneself washes/ethyl acetate, 2/1, V/V) tracking reaction.After reaction stops, solvent is steamed, residue ethyl acetate dissolves, filtering, filtrate is with 5% citric acid solution, saturated sodium bicarbonate solution, washing, and ester layer is through anhydrous sodium sulfate drying, filtering, Xuan Zheng Nong Shrink obtain the mg of head product 440, silica gel column chromatography(Solvent:Just oneself washes/ethyl acetate, and 2/1,
V/V), white solid 132mg is obtained.1HNMR(500 MHz, CDC13) δ:11.01 (s, 1H), 7.37 (dd, 1 Η, /=1.5,8.0 Hz), 7.09 (dd, 1H, /=1.5,8.0 Hz), 6.80 (t, 1H, the Hz of /=8.0), 5.65 (s, 1H), 4.35 (t, 2H, /=7.0 Hz), 1.78 (m, 2H), 1.44 (m, 2H), 1.27 1.35 (m, 12H), 0.88 (t, 3H, /=7.0 Hz);13C NMR (125 MHz, CDCI3) δ:170.8,148.9,145.0,120.5,120.0,119.6,119.1,65.7,31.9,29.5,29.3,29.2,28.5,27.6,25.9,22.7,14.1 ppm; IR (KBr) v: 3478, 2926, 2885, 1667, 1469, 1309, 1267, 1067, 753 cm"1; HRMS: m/z [M+H]+ calcd for C17H2704 +: 295.1904, found: 295.1910.
Compound I -5:2,3- dihydroxy-benzoic acid dodecane esters
Synthetic method with compound I -4, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(372 mg, 2 mmol) dodecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 180mg. 1H NMR (500 MHz, CDC13) δ:11.01 (s, 1 Η), 7.38 (dd, 1 Η, /=1.5,8.0 Hz), 7.10 (dd, 1 Η, /=1.0,8.0 Hz), 6.80 (t, 1H, the Hz of /=8.0), 5.64 (s, 1H), 4.35 (t, 2H, /=6.5 Hz), 1.78 (m, 2H), 1.44 (m, 2H), 1.26 1.35 (m, 16H), 0.88 (t, 3H, /=7.0 Hz); HRMS: m/z [M+H]+ calcd for C19H3104 +: 323.2217, found: 323.2236.
Compound I -6:2,3- dihydroxy-benzoic acid tetradecane esters
Synthetic method with compound I -4, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(428 mg, 2 mmol) tetradecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 150mg. 1H NMR (500 MHz, CDC13) δ:11.01 (s, 1 Η), 7.37 (dd, 1 Η, /=1.5,8.5 Hz), 7.10 (dd, 1 Η, /=1.0,8.0 Hz), 6.80 (t, 1H, the Hz of /=8.0), 5.63 (s, 1H), 4.35 (t, 2H, /=6.5 Hz), 1.78 (m, 2H), 1.44 (m, 2H), 1.26 1.35 (m, 20H), 0.88 (t, 3H, /=7.0 Hz);13C NMR (125 MHz, CDC13) δ:170.4,148.9,145.0,120.5,119.6,119.1,112.6,65.7,31.9,29.7 29.6,29.5,29.4,29.2,28.5,25.9,22.7,14.1 ppm; IR (KBr) v: 3485, 2917, 2849, 1669, 1467, 1310, 1267, 1157, 1067, 759 cm"1; HRMS: m/z [M+H]+ calcd for C21H3504 +: 351.2530, found: 351.2536.
Compound I -7:2,3- dihydroxy-benzoic acid hexadecane esters
Synthetic method with compound I -4, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(484 mg, 2 mmol) hexadecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 178 mg. 1H NMR (500 MHz, CDC13) δ:11.01 (s, 1 Η), 7.37 (dd, 1 Η, /=1.5,8.0 Hz), 7.10 (dd, 1 Η, /=1.0,8.0 Hz), 6.80 (t, 1H, the Hz of /=8.0), 5.65 (s, 1H), 4.35 (t, 2H, /=6.5 Hz), 1.78 (m, 2H), 1.44 (m, 2H), 1.25 1.35 (m, 24H), 0.88 (t, 3H, /=7.0 Hz); HRMS: m/z [M+H]+ calcd for C23H3904 +: 379.2843, found: 379.2848.
Compound I -8:2,3- dihydroxy-benzoic acid octadecane esters
Synthetic method with compound I -4, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(540 mg, 2 mmol) octadecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 170mg. 1H NMR (500 MHz, CDC13) δ:11.01 (s, 1 Η), 7.37 (dd, 1 Η, /=1.5,8.0 Hz), 7.10 (dd, 1 Η, /=1.0,8.0 Hz), 6.80 (t, 1H, the Hz of /=8.0), 5.63 (s, 1H), 4.35 (t, 2H, /=6.5 Hz), 1.78 (m, 2H), 1.44 (m, 2H), 1.25 1.35 (m, 28H), 0.88 (t, 3H, /=7.0 Hz);13C NMR (125 MHz, CDC13) δ:170.4,148.9,145.1,120.5,119.6,119.1,112.7,65.7,31.9,29.7 29.6,29.5,29.4,29.2,28.5,25.9,22.7,14.1 ppm; IR
(KBr) v: 3473, 2917, 2850, 1665, 1467, 1266, 1159, 1064, 799, 762 cm—1; HRMS: mJz [M+H]+ calcd for C25H4304 +: 407.3156, found: 407.3192.
Compound I -9:2,3- dihydroxy-benzoic acid eicosane esters
Synthetic method with compound I -4, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(896 mg, 3 mmol) eicosanol,(206 mg, 1 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 104 mg. 1H NMR (500 MHz, CDC13) δ:11.00 (s, 1 Η), 7.37 (dd, 1 Η, /=1.5,8.0 Hz), 7.10 (dd, 1 Η, /=0.5,8.0 Hz), 6.80 (t, 1H, the Hz of /=8.0), 5.63 (s, 1H), 4.34 (t, 2H, /=6.5 Hz), 1.78 (m, 2H), 1.43 (m, 2H), 1.25 1.35 (m, 32H), 0.88 (t, 3H, /=7.0 Hz);13C NMR (125 MHz, CDC13) δ:170.4,148.9,145.0,120.5,119.6,119.1,112.7,65.7,31.9,29.7 29.6,29.5,29.4,29.2,28.5,25.9,22.7,14.1 ppm; IR (KBr) v: 3403, 2919, 2850, 1675, 1467, 1313, 1254, 1159, 1067, 752 cm—1; HRMS: mJz [M+H]+ calcd for C27H4704 +: 435.3469, found: 435.3489.
Compound I -10:2,3- dihydroxy-benzoic acid docosane esters
Synthetic method with compound I -4, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(653 mg, 2 mmol) tadenan,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 102 mg. 1H NMR (500 MHz, CDC13) δ:11.01 (s, 1H), 7.37 (dd, 1 Η, /=1.5,8.0 Hz), 7.10 (dd, 1 Η, /=1.0,8.0 Hz), 6.80 (t, 1H, the Hz of /=8.0), 5.63 (s, 1H), 4.34 (t, 2H, /=6.5 Hz), 1.78 (m, 2H), 1.43 (m, 2H), 1.25 1.35 (m, 36H), 0.88 (t, 3H, /=7.0 Hz);13C NMR (125 MHz, CDC13) δ:170.4,148.9,145.1,120.5,119.6,119.1,112.7,65.7,31.9,29.7 29.6,29.5,29.4,29.2,28.5,25.9,22.7,14.1 ppm; IR (KBr) v: 3397, 2918, 2849, 1675, 1469, 1312, 1256, 1158, 1065, 750 cm"1; HRMS: m/z [M+H]+ calcd for C29H5104 +: 463.3782, found: 463.3790.
Compound I -11:2,3- dihydroxy-benzoic acid melissane esters
Synthetic method with compound I -4, reaction feed intake for:(154 mg, l mmol) 2,3- dihydroxy-benzoic acids,(1.32 g, 3 mmol) triacontanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 20 ml tetrahydrofurans, acquisition white solid 75 mg. 1H NMR (500 MHz, CDC13) δ:11.00 (s, 1H), 7.37 (dd, 1 Η, /=1.5,8.5 Hz), 7.10 (dd, 1 Η, /=1.0,8.0 Hz), 6.80 (t, 1H, the Hz of /=8.0), 5.63 (s, 1H), 4.34 (t, 2H, /=6.5 Hz), 1.77 (m, 2H), 1.45 (m, 2H), 1.25 1.35 (m, 52H), 0.88 (t, 3H, /=7.0 Hz);13C NMR (125 MHz, CDC13) δ:164.5,149.4,145.0,120.5,119.6,119.1,112.6,65.7,34.9,31.9,29.7 29.5,29.4,29.2,28.5,25.9,25.4,24.7,22.7,14.1 ppm; IR (KBr) v:3484,2920,2848,1665,1468,1313,1262,1162,1076,801 cm-1; MS (m z): 575 [M]+.
Compound I -12:2,6-DHBA tetradecane ester
Synthetic method with compound I -4, reaction feed intake for:(154 mg, 1 mmol) 2,6-DHBA,(428 mg, 2 mmol) tetradecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 66 mg. 1H NMR (500 MHz, CDC13) δ:9.79 (s, 2H), 7.32 (t, 1H, the Hz of J=8.5), 6.48 (d, 2H, J=8.5 Hz), 4.35 (t, 2H, /=6.5 Hz), 1.78 (m, 2H), 1.44 (m, 2H), 1.26 1.35 (m, 20H), 0.88 (t, 3H, /=7.0 Hz);13C NMR (125 MHz, CDC13) δ:169.8,149.3,145.4,160.9,136.5,108.2,100.1,66.7,53.4,31.9,29.6 29.7,29.5,29.4,29.3,29.1,28.5,25.9,22.7,14.1 ppm; IR (KBr) v:3472,2919,2849,1669,1630,
1576,1465,1327,1293,1156,1067,782 cm "1; HRMS: m/z [M+H]+ calcd for C21H3504 +: 351.2530, found: 351.2516.
Compound I -13:2,6-DHBA eicosane ester
Synthetic method with compound I -4, reaction feed intake for:(154 mg, 1 mmol) 2,6- dihydroxy-benzoic acids,(597 mg, 2 mmol) eicosanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 104 mg. 1H NMR (500 MHz, CDC13) δ:9.79 (s, 2 Η), 7.31 (t, 1H, the Hz of /=8.5), 6.48 (d, 2H, /=8.5 Hz), 4.50 (t, 2H, /=6.5 Hz), 1.83 (m, 2H), 1.43 (m, 2H), 1.25 1.35 (m, 32H), 0.88 (t, 3H, /=7.0 Hz); MS (m/z): 434 [M]+.
Compound I -14:2,4- dihydroxy-benzoic acid tetradecane esters
Synthetic method with compound I -4, reaction feed intake for:(154 mg, 1 mmol) 2,4- dihydroxy-benzoic acids,(428 mg, 2 mmol) tetradecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 158 mg. 1H NMR (500 MHz, CDC13) δ:11.06 (s, 1H), 7.74 (d, /=8.5 Hz, 1H), 7.54 (m, 1H), 6.38 (m, 1H), 5.39 (s, 1H), 4.30 (t, /=6.5 Hz, 2H), 1.76 (m, 2H), 1.41 (m, 2H), 1.25 1.35 (m, 20H), 0.88 (t, /=7.0 Hz, 3H) ppm; HRMS: m/z [M+H]+ calcd for C21H3504 +: 351.2530, found: 351.2557.
Compound I -15:PCA tetradecane ester
Synthetic method with compound I -4, reaction feed intake for:(154 mg, 1 mmol) 2,4- dihydroxy-benzoic acids,(428 mg, 2 mmol) tetradecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 180 mg. 1H NMR (500 MHz, CDC13) δ:7.59 (d, J=2.0 Hz, 1H), 7.57 (dd, J=2.0,8.0 Hz, 1H), 6.91 (d, J=8.5 Hz, 1H), 4.26 (t, /=6.5 Hz, 2H), 1.73 (m, 2H), 1.42 (m, 2H), 1.25 1.37 (m, 20H), 0.89 (t, /=7.0 Hz, 3H) ppm; HRMS: m/z [M+H]+ calcd for C21H3504 +: 351.2530, found: 351.2551.
Compound I -16:Gallic Acid tetradecane ester
Synthetic method with compound I -4, reaction feed intake for:(170 mg, 1 mmol) Gallic Acid,(428 mg, 2 mmol) tetradecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 176 mg. 1H NMR (500 MHz, CDC13) δ:7.24 (s, 2H), 4.24 (t, /=6.5 Hz, 2H), 1.72 (m, 2H), 1.41 (m, 2H), 1.25 1.35 (m, 20H), 0.88 (t, J=7.0 Hz, 3H) ppm; HRMS: m/z [M+H]+ calcd for C21H3505 +: 367.2479, found: 367.2473.
Compound I -17:2 hydroxybenzoic acid tetradecane ester
Synthetic method with compound I -4, reaction feed intake for:(138 mg, 1 mmol) 2 hydroxybenzoic acid,(428 mg, 2 mmol) tetradecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 164 mg. 1H NMR (500 MHz, CDC13) δ:10.88 (s, 1H), 7.37 (m, 1H), 7.10 (m, 1H), 6.91 (m, 1H), 6.80 (t, 1H, J=8.0 Hz), 4.35 (t, 2H, /=6.5 Hz), 1.78 (m, 2H), 1.44 (m, 2H), 1.26 1.35 (m, 20H), 0.88 (t, 3H, /=7.0 Hz); HRMS: m/z [M+H]+ calcd for C21H3503 +: 335.2581 , found: 335.2564.
Compound I -18:3- hydroxybenzoic acid tetradecane esters
Synthetic method with compound I -4, reaction feed intake for:(138 mg, 1 mmol) 3- hydroxybenzoic acids,(428 mg, 2 mmol) tetradecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 174 mg. 1H NMR (500 MHz, CDC13) δ:7.57 (m, 1H), 7.37 (m, 1H), 7.25 (m, 1H), 7.01 (m, 1H), 5. 67 (s,
1H), 4.35 (t, 2H, /=6.5 Hz), 1.78 (m, 2H), 1.44 (m, 2H), 1.26 1.35 (m, 20H), 0.88 (t, 3H, /=7.0
Hz); MS (m/z): 334 [M]+.
Compound I -19:2,3- dimethoxybenzoic acid tetradecane esters
Synthetic method with compound I -4, reaction feed intake for:(182 mg, l mmol) 2,3- dimethoxybenzoic acids,(428 mg, 2 mmol) tetradecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 162 mg. 1H NMR (500 MHz, CDC13) δ:7.08 (t, 1 Η, /=7.5 Hz), 6.95 (dd, 1H, /=1.5,8.0 Hz), 6.79 (dd, 1H:/=1.0,7.0 Hz), 4.35 (t, the Hz of 2H, J=6.5), 3.92 (s, 3H), 3.88 (s, 3H), 1.78 (m, 2H), 1.44 (m, 2H), 1.26 1.35 (m, 20H), 0.88 (t, 3H, /=7.0 Hz);13C NMR (125 MHz, CDC13) δ:166.4,153.5,148.9,126.6,123.8,122.2,115.6,65.3,61.5,56.0,31.9,29.7 29.6,29.5,29.3,29.2,28.7,26.0,22.7,14.1 ppm; IR (KBr) v:2926,2855,1726,1587,1474,1266,1148,1062,754 cm "1; HRMS: m/z [ +H]+ calcd for C23H3904 +: 379.2843, found: 379.2865.
Compound I -20:2,3- dimethoxybenzoic acid octadecane esters
Synthetic method with compound I -4, reaction feed intake for:(182 mg, l mmol) 2,3- dimethoxybenzoic acids,(540 mg, 2 mmol) octadecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 170 mg. 1H NMR (500 MHz, CDC13) δ:7.06 (t, 1H, /=8.0 Hz), 6.93 (dd, 1H, /=1.5,8.0 Hz), 6.77 (dd, 1H:/=1.5,8.0 Hz), 4.35 (t, the Hz of 2H, J=6.5), 3.92 (s, 3H), 3.88 (s, 3H), 1.78 (m, 2H), 1.44 (m, 2H), 1.25 1.35 (m, 28H), 0.88 (t, 3H, /=7.0 Hz); MS (m z): 434 [M]+.
Compound I -21:2- hydroxy 3-methoxybenzene formic acid tetradecane esters
Synthetic method with compound I -4, reaction feed intake for:(168 mg, 1 mmol) 2- hydroxy 3-methoxybenzenes formic acid, 428 mg, 2 mmol) tetradecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition yellow liquid 109 mgo 1H NMR (500 MHz, CDC13) δ:11.12 (s, 1H), 7.44 (dd, /=1.5,8.5 Hz, 1H), 7.04 (dd, 1H, J=1.5,8.0 Hz, 1H), 6.83 (t, /=8.0 Hz, 1H), 4.34 (t, /=6.5 Hz, 2H), 3.91 (s, 3H), 1.77 (m, 2H), 1.44 (m, 2H), 1.25 1.36 (m, 20H), 0.88 (t, J=7.0 Hz, 3H) ppm;13C NMR (125 MHz, CDC13) δ:170.5,152.1,148.5,121.0,118.4,116.4,112.9,65.6,56.2,31.9,29.7 29.6,29.5,29.3,29.2,28.5,25.9,22.7,14.1 ppm; IR (KBr) v:3080,2923,2849,1667,1587,1466,1341,1242,1167,1062,767 cm1; HRMS: m/z [M+H]+ calcd for C22H3704 +: 365.2686, found: 365.2654.
Compound I -22:2- chlorobenzoic acid tetradecane esters
Synthetic method with compound I -4, reaction feed intake for:(156 mg, 1 mmol) 2- chlorobenzoic acids,(428 mg, 2 mmol) tetradecanol,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 150 mg. 1H NMR (500 MHz, CDC13) δ:7.65 (m, 1H), 7.30 (m, 2H), 7.08 (m, 1H), 4.35 (t, 2H, /=6.5 Hz), 1.78 (m, 2H), 1.44 (m, 2H), 1.26 1.35 (m, 20H), 0.88 (t, 3H, /=7.0 Hz); MS (m z): 352 [M]+.
Compound I -23:2,3- dihydroxy-N- myristyl benzamides
Will(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(135 mg, 1 mmol) I-hydroxybenzotriazole hydrate,(253 mg, 1.1 mmol) tetradecylamine, 10 ml tetrahydrofurans are placed in 25 ml round-bottomed flasks, cold to cause 0 °C, are added(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 4 h are stirred at room temperature.Use thin-layer chromatography(Solvent:Just oneself washes/ethyl acetate, 3/1, V/V) tracking reaction.After reaction stops, solvent is steamed, residue ethyl acetate dissolves, filtered, filtrate is molten with saturated sodium bicarbonate
Liquid, washing, ester layer obtain the mg of head product 440 through anhydrous sodium sulfate drying, filtering, Xuan Zheng Nong Shrink, and silica gel column chromatography obtains the mg of white solid 265.1L^NMR (500MHz, CDC13) δ:12.81 (s, 1H), 7.04 (dd, /=1.0,8.0 Hz, 1H), 6.87 (dd, /=1.0,8.0 Hz, 1H), 6.76 (t, /=8.0 Hz, 1H), 6.30 (s, 1H), 5.78 (s, 1H), 3.44 (m, 2H), 1.62 (m, 2H), 1.25 1.40 (m, 22H), 0.88 (t, /=7.5 Hz, 3H) ppm;13C NMR (125 MHz, CDC13) δ:169.9,149.1,146.0,118.5,117.9,115.7,114.0,39.7,31.9,29.7 29.6,29.5,29.4,29.3,29.2,26.9,22.7,14.1 ppm; IR (KBr) v:3482,3389,3268,2920,2850,1639,1586,1546,1462,1338,1270,1236,1176,1077,723,746 cm "1; HRMS: m/z [M+Na]+ calcd for C21H35N03Na+: 372.2509, found:372.2499. compound I -24:2,3- dihydroxy-N- octyl group benzamides
Synthetic method with compound I -23, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(185 mg, 1 mmol) octylame,(135 mg, 1 mmol) I-hydroxybenzotriazole hydrate,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 158 mgo 1HNMR (500 MHz, CDC13) δ:12.81 (s, 1 Η), 7.04 (d, /=8.0 Hz, 1H), 6.86 (d, /=8.5 Hz, 1H), 6.76 (t, /=8.0 Hz, 1H), 6.31 (s, 1H), 5.78 (s, 1H), 3.44 (q, J=7.0 Hz, 2H), 1.63 (m, 2H), 1.27 1.39 (m, 10H), 0.88 (t, /=7.0 Hz, 3H); MS (m/z):265 [M]+compounds I -25:2,3- dihydroxy-N- dodecyl benzamides
Synthetic method with compound I -23, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(428 mg, 2 mmol) dodecyl amine, (135 mg, 1 mmol) I-hydroxybenzotriazole hydrate,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 158 mg. 1H NMR (500 MHz, CDC13) δ:12.81 (s, 1H, Ph2-OH), 7.04 (dd, /=1.0,8.0 Hz, 1H), 6.87 (dd, /=1.0,8.5 Hz, 1H), 6.75 (t, /=8.0 Hz, 1H), 6.32 (s, 1H), 5.80 (s, 1H), 3.44 (q, /=7.0 Hz, 2H), 1.62 (m, 2H), 1.25 1.40 (m, 10H), 0.88 (t, /=7.0 Hz, 3H); MS (m/z): 321 [M]+.
Compound I -26:2,3- dihydroxy-N- cetyl benzamides
Synthetic method with compound I -23, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(241 mg, 1 mmol) cetylamine, (135 mg, 1 mmol) I-hydroxybenzotriazole hydrate,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 308 mg. 1H NMR (500 MHz, CDC13) δ:12.81 (s, 1H, Ph2-OH), 7.04 (dd, /=1.0,8.0 Hz, 1H), 6.86 (dd, /=1.0,8.5 Hz, 1H), 6.75 (t, /=8.0 Hz, 1H), 6.30 (s, 1H), 5.77 (s, 1H), 3.44 (q, J=6.5 Hz, 2H), 1.61 (m, 2H), 1.25 1.40 (m, 10H), 0.88 (t, /=7.0 Hz, 3H); MS (m/z): 377 [M]+.
Compound I -27:2,3- dihydroxy-N- octadecyl benzamides
Synthetic method with compound I -23, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(269 mg, 1 mmol) octadecylamine, (135 mg, 1 mmol) I-hydroxybenzotriazole hydrate,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 340mg. 1H NMR (500 MHz, CDC13) δ:12.81 (s, 1H, Ph2-OH), 7.04 (the Hz of dd, J=1.0,8.0,1H), 6.87 (dd, /=1.0,8.0 Hz, 1H), 6.76 (t, /=8.0 Hz, 1H), 6.30 (s, 1H), 5.77 (s, 1H), 3.44 (q, /=6.5 Hz, 2H), 1.63 (m, 2H), 1.25 1.38 (m, 30H), 0.88 (t, /=7.5 Hz, 3H); MS (m/z): 405 [M]+.
Compound I -28:2,3- dimethoxy-N- myristyl benzamides
Synthetic method with compound I -23, reaction feed intake for:(182 mg, 1 mmol) 2,3- dimethoxybenzoic acids,(230mg, l
Mmol) tetradecylamine,(135 mg, 1 mmol) I-hydroxybenzotriazole hydrate,(250 mg, 1.2mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 305 mg.1H NMR (500 MHz, CDC13) δ:7.97 (s, 1 Η, Ν Η), 7.68 (dd, /=1.0,8.0 Hz, 1 Η), 7.14 (t, /=8.0 Hz, 1H), 7.02 (dd, /=1.0,8.0 Hz, 1H); MS (mz): 377 [M]+.
Compound I -29:3,4- dihydroxy-N- myristyl benzamides
Synthetic method with compound I -23, reaction feed intake for:(154 mg, 1 mmol) 2,3- dihydroxy-benzoic acids,(230 mg, 1 mmol) tetradecylamine,(135 mg, 1 mmol) I-hydroxybenzotriazole hydrate,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 297 mg. 1H NMR (500 MHz, CDC13) δ:7.66 (d, /=2.0 Hz, 1H), 7.09 (dd, /=2.0,8.0 Hz, 1H), 6.88 (d, /=8.0 Hz, 1H), 6.12 (s, 1H), 3.43 (m, 2H), 1.93 (m, 2H), 1.25 1.39 (m, 22H), 0.88 (t, /=7.0 Hz, 3H) ppm;13C NMR (125 MHz, CDC13) δ:167.9,148.0,144.1,118.8,115.5,115.7,114.0,40.3,31.9,29.7 29.6,29.5,29.3,27.0,22.7,14.1 ppm; IR (KBr) v: 3494, 3382, 3182, 2921, 2851, 1587, 1517, 1467, 1439, 1294, 1169, 1106, 769 cm—1; HRMS: mJz [M+H]+ calcd for C21H36N03 +: 350.2690, found: 350.2683.
Compound I -30:3,4,5- trihydroxy-N- myristyl benzamides
Synthetic method with compound I -23, reaction feed intake for:(170 mg, 1 mmol) Gallic Acid,(230 mg, 1 mmol) tetradecylamine,(135 mg, 1 mmol) I-hydroxybenzotriazole hydrate,(250 mg, 1.2 mmol) dicyclohexylcarbodiimide, 15 ml tetrahydrofurans, acquisition white solid 314 mg. 1HNMR (500 MHz, CDC13) S:7.34 7.37 (m, 3H), 3.65 (t, /=8.0 Hz, 2H), 2.26 (s, 3H), 2.24 (s, 3H), 1.52 (m, 2H), 1.21 1.31 (m, 22H), 0.88 (t, /=7.0 Hz, 3H); MS (m/z): 365 [M]+.
Compound I -31:(washing) acid amides of N- (3,4- Dimethoxyphenyl) 14
Synthetic method with compound I -23, reaction feed intake for:(312mg, 2mmol) 3,4- dimethoxyanilines,(465 mg, 2 mmol) tetradecanoic acid, (135 mg, 1 mmol) I-hydroxybenzotriazole hydrate,(450 mg, 2.2 mmol) dicyclohexylcarbodiimide, 30 ml tetrahydrofurans, acquisition white solid 560mg. 1H NMR (500 MHz, CDC13) δ:7.40 (d, /=2.0 Hz, 1H), 7.05 (s, 1H), 6.82 (dd, /=2.0,8.5 Hz, 1H), 6.80 (s, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 2.33 (t, /=7.5 Hz, 2H), 1.72 (m, 2H), 1.25 1.40 (m, 20H), 0.88 (t, J=7.0 Hz, 3H) ppm; MS (m/z):363 [M]+compounds I -32:(washing) acid amides of N- (3,4- dihydroxyphenyl) 14
(150 mg, 0.41 mmol) compound 1-31 is dissolved in 10 ml dichloromethane, Boron tribromide (0.3 ml, 3 mmol) is added dropwise under zero degree, completion of dropping is warmed to room temperature, and is stirred overnight.After reaction terminates, it is quenched under zero degree with methanol, decompression steams solvent, the extraction of residue ethyl acetate, water washing, anhydrous sodium sulfate drying.Silica gel column chromatography (solvent:Petrol ether/ethyl acetate, 8/1, V/V) obtain white solid 118 mgo 1H NMR (500 MHz, CDC13) δ:7.29 (d, /=2.0 Hz, 1H), 7.15 (s, 1H), 6.79 (d, /=8.5 Hz, 1H), 6.40 (dd, /=2.5,8.5 Hz, 1H), 5.30 (s, 2H), 2.38 (t, /=7.5 Hz, 2H), 1.74 (m, 2H), 1.26 1.40 (m, 20H), 0.88 (t, /=7.0 Hz, 3H) ppm; MS (mz): 335 [M]+.
Compound I -33:L- (3, the 4- Dimethoxyphenyl) tetradecane -1- ketone
By tetradecanoic acid(2.28g, 0.01 mol) 30 ml thionyl chlorides are dissolved in, backflow under a nitrogen is stayed overnight, excessive S0C12Vacuum distillation is eliminated, and obtains myristyl acyl chlorides.The ml of 1,2- dimethoxy benzene 2 is dissolved in 20 ml carbon disulfide, and A1C1 is added portionwise under stirring3(1.4 g, 10 mmol) are stirred for 15 minutes after adding, and acyl chlorides is added dropwise, and continue to stir 4 hours.Reaction is finished, and will be reacted
Liquid is poured into 30 ml frozen water until reddish brown decoloration.Ethyl acetate is extracted, anhydrous sodium sulfate drying, filtering , Nong Shrink.Silica gel column chromatography (solvent:Petrol ether/ethyl acetate, 10/1, V/V) obtain the g of white solid 2.6.1H NMR (500 MHz, CDCl3) δ:7.58 (the Hz of dd, J=2.0,8.5,1H), 7.53 (the Hz of d, J=2.0,1H), 6.88 (the Hz of d, J=8.5,1H), 6.92 (the Hz of d, J=8.5,1H), 3.95 (s, 3H), 3.94 (s, 3H), 2.92 (t, /=7.5 Hz, 2H), 1.72 (m, 2H), 1.25 1.40 (m, 20H), 0.88 (t, /=6.5 Hz, 3H) ppm; HRMS: m/z [M+H]+ calcd for C22H3703 +: 349.2737, found:349.2715. compound I -34:L- (3, the 4- dihydroxyphenyl) tetradecane -1- ketone
(348mg, 1 mmol) compound 1-33 is dissolved in 20 ml dichloromethane, Boron tribromide (0.6 ml, 6 mmol) is added dropwise under zero degree, completion of dropping is warmed to room temperature, and is stirred overnight.After reaction terminates, it is quenched under zero degree with methanol, decompression steams solvent, the extraction of residue ethyl acetate, water washing, anhydrous sodium sulfate drying.Silica gel column chromatography (solvent:Petrol ether/ethyl acetate, 8/1, V/V) obtain white solid 65mg. 1H NMR (500 MHz, CDC13) δ:7.67 (d, /=2.0 Hz, 1H), 7.50 (dd, /=2.0,8.5 Hz, 1H), 6.92 (d, /=8.5 Hz, 1H), 6.17 (s, 1H), 5.87 (s, 1H), 2.90 (t, /=7.5 Hz, 2H), 1.71 (m, 2H), 1.25 1.37 (m, 20H), 0.88 (t, J=6.5 Hz, 3H) ppm; HRMS: m/z [ +H]+ calcd for C20H33O3 +: 321.2424, found: 321.2434.
Compound I -35:3- (tetradecyloxyaniline carbonyl) -1,2- phenyl diacetates
By (140 mg, 0.4 mmol) compound I -6, (49 mg, 0.4 mmol) 4-dimethylaminopyridine DMAP is dissolved in the pyridine of 4ml dryings, and stirring is lower to be added dropwise 1ml acetic anhydride, and 5h is stirred at room temperature.Reaction is finished, and is extracted with ethyl acetate, and 1M HC1, water washing, anhydrous sodium sulfate drying are used successively.Silica gel column chromatography(Solvent:Just oneself washes/ethyl acetate, 5/1, V/V) white solid 130mgo 1H NMR (500 MHz, CDC13) δ:7.90 (dd, /=1.0,7.5 Hz, 1H), 7.37 (dd, /=1.0,8.0 Hz, 1H), 7.32 (t, /=8.0 Hz, 1H), 4.26 (t, /=6.5 Hz, 2H), 2.34 (s, 3H), 2.32 (s, 3H), 1.72 (m, 2H), 1.40 (m, 2H), 1.26 1.33 (m, 20H), 0.88 (t, /=7.0 Hz, 3H);13C NMR (125 MHz, CDC13) δ:168.4,168.2,163.9,143.5,142.6,128.9,127.6,126.0,125.2,65.6,31.9,29.6 29.7,29.5,29.4,28.6,25.9,22.7,20.6,14.1; IR (KBr) v: 2919, 2850, 1775, 1710, 1463, 1375, 1306, 1294, 1197, 1106, 761 cm—1; HRMS: m/z [ +H]+ calcd for C25H3906 +: 435.2741 , found: 435.2752.
Compound I -36:3- (myristyl formoxyl) -1,2- phenyl diacetates
Synthetic method with compound 1-35, reaction feed intake for:(100 mg, 0.29 mmol) compound 1-23, (37 mg, 0.3 mmol) DMAP, (0.6 ml) acetic anhydride, 2 ml dry pyridines obtain weak yellow liquid 1 10 mg. 1H NMR (500 MHz, CDC13) δ:7.34 7.37 (m, 3H), 3.65 (t, /=8.0 Hz, 2H), 2.26 (s, 3H), 2.24 (s, 3H), 1.52 (m, 2H), 1.21 1.31 (m, 22H), 0.88 (t, /=7.0 Hz, 3H); MS (m/z): 434 [M]+.
Compound I -37:5- (tetradecyloxyaniline carbonyl) benzene -1,2,3- triacetates
Synthetic method with compound I -35, reaction feed intake for:(28 mg, 0.076 mmol) compound I -17, (12 mg, 0.1 mmol) DMAP, (0.3 ml) acetic anhydride, 1 ml dry pyridines, acquisition white solid 29 mg. 1H NMR (500 MHz, CDC13) δ:7.80 (s, 3 Η), 4.31 (t, /=6.5 Hz, 2H), 2.32 (s, 9H), 1.75 (m, 2H), 1.21 1.31 (m, 22H), 0.88 (t, J=7.0 Hz, 3H); MS (m/z): 492 [M]+.
Compound I -38:5- (myristyl formoxyl) benzene -1,2,3- triacetates
Synthetic method with compound I -35, reaction feed intake for:Compound I -31 (100 mg, 0.27 mmol) (37 mg, 0.3 mmol) DMAP, acetic anhydride (0.6 ml), 2 ml dry pyridines obtain the mg of white solid 1 13. 1H NMR (500 MHz, CDC13)
δ:7.53 (s, 2H), 6.04 (s, 1H), 3.42 (q, /=6.5 Hz, 2H), 2.32 (s, 9H), 1.59 (m, 2H), 1.27 1.39 (m, 22H), 0.89 (t, /=7.0 Hz, 3H); MS (m z): 491 [M]+.
Compound I -39:The acid esters of 1,2- phenylene 20
Synthetic method with compound I -4, reaction feed intake for:O-phenol(110 mg, 1 mmol), arachic acid(310 mg, 1 mmol), dicyclohexylcarbodiimide(250 mg, 1.2 mmol), 15 ml tetrahydrofurans obtain the mg of white solid 391. 1H NMR (500 MHz, CDC13) δ:7.13 7.16 (t, 1H, /=7.5 Hz), 7.09 7.11 (d, 1H, /=7.5 Hz), 7.02 7.04 (d, 1H, J=1.5 Hz), 6.92 6.95 (t, 1H, /=7.5 Hz), 2.63 (t, 2H, /=6.5 Hz), 2.42 (t, 2H, the Hz of /=6.5), 1.96 1.99 (m, 12H), 1.17 1.42 (m, 60H), 0.89 (bs, 6H); MS (m z): 699 [M]+.
Compound I -40:2,3- dihydroxyphenyl 14 (alkane) hydrochlorates
Synthetic method with compound I -4, reaction feed intake for:Adjacent trisphenol (126 mg, 1 mmol), tetradecanoic acid (456 mg, 2 mmol), dicyclohexylcarbodiimide(250 mg, 1.2 mmol), 15 ml tetrahydrofurans obtain the mg of white solid 120. 1H NMR (500 MHz, CDCI3) δ:6.82 (m, 1H), 6.61 (dd, J=3.0,7.0 Hz, 1H), 6.57 (d, /=8.0 Hz, 1H), 5.74 (s, 1H), 5.30 (s, 1H), 2.64 (m, 2H), 1.77 (m, 2H), 1.41 (m, 2H), 1.26 1.35 (m, 18H), 0.88 (t, /=6.5 Hz, 3H) ppm;13C NMR (125 MHz, CDC13) δ:173.2,148.0,146.9,126.8,121.1,113.4,112.8,109.7,34.4,34.1,31.9,29.6 29.7,29.4,29.3,29.2,29.0,24.9,22.7,14.1 ppm; IR (KBr) v: 3551 , 3341 , 2920, 2848, 1735, 1604, 1473, 1413, 1273, 1142 cm"1; HRMS: mJz [M+H]+ calcd for C20H33O4 +: 337.2373, found: 337.2361.
Compound I -41:3- (tetradecane oxygen) benzene -1,2- glycol
By adjacent triphenol(200 mg, 1.58 mmol), tetradecyl alchohol(339 mg, 1.58 mmol), triphenyl phosphorus(414 mg, 1.58 mmol) it is added in anhydrous tetrahydro furan, diethyl azodiformate is added dropwise under ice bath(275 mg, 1.58 mmol), room temperature reaction is stayed overnight, and reaction is finished, and removes solvent , Nong Shrink fluid columns chromatography (solvent under reduced pressure:Petrol ether/ethyl acetate, 20/1, VA, obtain the mg of light red solid 220.1H NMR (500 MHz, CDC13) δ:6.73 (t, /=6.5 Hz, 1H), 6.58 (dd, /=1.0,8.0 Hz, 1H), 6.45 (dd, /=1.0,8.5 Hz, 1H), 5.41 (s, 1H), 5.29 (s, 1H), 4.02 (t, /=6.5 Hz, 2H), 1.80 (m, 2H), 1.44 (m, 2H), 1.26 1.36 (m, 20H), 0.88 (t, /=6.5 Hz, 3H) ppm;13C NMR (125 MHz, CDC13) δ:146.4,144.1,132.7,119.7,108.6,104.1,69.2,31.9,29.6 29.7,29.4,29.3,26.0,22.7,14.1 ppm; IR (KBr) v: 3444, 3373, 2922, 2851 , 1627, 1526, 1471 , 1234, 1178, 1071 , 765, 717 cm—1; HRMS: mJz [M+H]+ calcd for C2。H3503 +: 323.2581 , found: 323.2560.
Embodiment 2, benzoate derivatives have the effect of nerve growth factor
2-1:
Research finds that NGF can prevent or reduce the regression of neuron, with promotion nerve growth and neuroprotection.Because the cells of PC 12 have the general features of nerve cell, PC12 cells can stop division in the presence of NGF, grow projection, change into neuron cell.Accordingly, it is capable to cause PC12 cell transformations that there is the application value prevented and treat the nerve degenerative diseases such as senile dementia into the compound of neuron cell.
Experimental implementation:
1) culture of the cells of PC 12:Meet 20x l04The individual cells of PC 12 are in 100 mm culture dish, the DMEM culture mediums of ml containing lO(Wherein contain 10% horse serum, 5% hyclone), a subculture was changed two days later, after three days subcultures.First use
PBS washes cell twice, 10 ml PBS is added in culture dish, in 37 °C, 5% C02Incubator in culture 10 minutes, purging, be transferred to 15 ml disposable centrifuge tube, after centrifugation on blood counting chamber count.24 porocyte culture plates first add DMEM culture mediums of the l ml containing serum per hole, after cell count, and 2 are connect per hole><104Individual cell, C02Incubator culture is loaded after 24 hours.
2) active testing:Using DMSO as negative control, the ng of NGF 40 are positive control, and compound I is configured to the DMSO solution of various concentrations.With DMEM solution of 1 ml containing 1% DMSO and sample(Without serum)After the former culture medium in every hole of 24 porocyte plates is replaced, 37 V, 5% C0 are put into2Incubator in cultivate.Every 24 hours, observation cellular morphology change in continuous 6 days under inverted microscope, the nervous process differentiation rate of cell is recorded(Nervous process is longer than total cell number purpose ratio under the cell number of one times of cell space diameter and the visual field), about 100 cells under each visual field are randomly selected at 3, averaged, and count mapping analysis.
) experimental result:
The series compound I of table 1. after 48 hours the cells of optium concentration PC 12 nervous process differentiation rate compound optium concentration(μ Μ) nervous process point
I -1 10 37
I -2 3 35
I -3 3 73
I -4 1 80
I -5 1 82
I -6(ABG-001) 1 87
I -7 1 82
I -8 3 82
I -9 10 79
I -10 10 70
I -11 30 61
I -12 3 27
I -13 3 25
I -14 1 36
I -15 3 83
I -16 0.3 80
I -17 3 32
I -18 3 28
I -19 10 30
I -20 10 33
I -21 1 32
I -22 3 27
I -23 0.03 61
I -24 0.03 58
I -25 0.1 35
I -26 0.1 50
I -27 0.1 39
-28 0.1 49
-29 1 73
-30 0.3 53
-31 3 30
-32 3 57
-33 1 84
-34 3 15
-35 0.3 71
-36 0.3 68
-37 0.3 70
-38 0.3 65
-39 3 40
-40 3 37
-41 0.3 44
Negative control(DMSO) 1% 10
Positive control (NGF) 40ng/ml 83
Preliminary pharmacological test result is shown:The connected mode of long alkyl chains, species, position and the number of benzene ring substituents, phenyl ring and side chain has a major impact to the cellular neural projection activity of PC 12.The nervous process differentiation rate of wherein compound 1-4,1-5, I -6 (ABG-001), I -7, I -8, I -9, I -10, I -15, I -16 in the cells of optium concentration PC 12 after 48 hours is suitable or higher with positive control NGF, and these compounds have the meaning further researched and developed.
Fig. 1 is to add compound ABG-001, and the nervous process differentiation rate of the cells of PC 12 is with the increased change of dosage after 48 hours, C in figure:1% DMS0 is negative control;NGF C40ng/ml) it is positive control, compound ABG-001 concentration unit μ Μ.
Fig. 2 is to add compound ABG-001, the microphoto of the cellular neural projections of PC 12 after 48 hours, schemes a, and 1% DMSO is negative control;Scheme b, the ng/ml of NGF 40 are positive control;Scheme c, compound ABG-001 concentration is 1 μ Μ. 2-2:
1,25 (Ο Η)2Vitamine D3 is by activating it by physical efficiency inducing neural growth factor(NGF expression).Our research finds that compared with brood wild-type mice, let- hydroxylases strike DNA murine and NGF expression reduction and hippocampal neural aregeneratory occur.Supplement l, 25 (OH)2Vitamine D3 or NGF can improve the nerve regneration that let- hydroxylases strike DNA murine.
Test main material:The experimental animal model lacked from 12 week old targeting knock out let- '-hydroxylase genes mouse as adult NGF.(Develop cooperatively with Canada McGill University this research department)
Experimental implementation:12 week old let- hydroxylases strike DNA murine and give B U intraperitoneal injections.And fixed brain tissue is irrigated through left ventricle with 4% paraformaldehyde after 10 days, BrdU immunostainings are carried out, newborn neuron is marked.ABG-001 is dissolved in
In 99.5% ethanol, then it is administered orally with normal saline dilution.
Experimental result(Fig. 3):With NGF treatment groups(Intracerebroventricular administration)Compare, ABG-001 intraperitoneal administrations can effectively improve the nerve regneration function that let- hydroxylases strike DNA murine;From Fig. 3 (a), compared with wild-type mice (+/+) compare, let- hydroxylases strike DNA murine(-/-) hippocampus nerve growth factor(NGF substantially reduction) is expressed;From Fig. 3 (b), compared with wild-type mice, hydroxylase strikes the reduction of DNA murine hippocampus neonatal neuron survival.NGF is treated(The ventricles of the brain are administered)The neonatal neuron survival that hydroxylase strikes DNA murine can be improved.Compared with NGF treatment groups, ABG-001 treatments(Intraperitoneal administration)The nerve regneration obstacle caused by NGF lacks can effectively be improved.
2-3:
Start in hippocampal dentate submicron particle area within the 3rd day after brain Temporary ischemia(SGZ) there is cell propagation increase, the peaks for 7-10 days, then declines.In recent years research finds that the newborn nerve cell of cerebral ischemia induction is most dead in 1-2 weeks after birth.Although cerebral ischemia can activate NSC, the nerve regneration of stimulation of endogenous, but the limited amount of precursor propagation, and the newborn nerve cell migration of regulation, differentiation, survival, neuron reparation and Synaptic formation the factor it is also not enough, the effect of itself reparation neurologic impairment can not be reached by regenerating after cerebral ischemia endogenous neural.Therefore, the death of newborn nerve cell how is reduced, promotes it to be migrated to ischemic necrosis stove, is induced to differentiate into functional neuron, play endogenous neurogenesis effect has turned into the focus that current ischemic brain damage is studied.The propagation of NSC, migration, differentiation are regulated and controled by many inside and outside environmental factor interactions.Although mechanism of nerve regeneration is still unclear at present after cerebral ischemia, the nerve regneration that neurotrophic factor gene knocks out after mouse cerebral ischemia substantially weakens, and intraventricular injection neurotrophic factor can promote stem cells hyperplasia, promotes newborn nerve cell number increase.
Test main material:Sprague-Dawley (SD) rat(Male and each 10 of female), body weight 200g 250g, purchased from Jiangsu Province's Experimental Animal Center.
Experimental implementation:10% chloraldurate intraperitoneal anesthesia, ligation right carotid and external carotid artery, internal carotid distal end is closed with artery clamp folder, and fishing line is inserted into internal carotid distal end, is implemented arteria cerebri media and is blocked for 60 minutes(Middle cerebral artery occlusion abbreviation MCAO in figure), prepare focal cerebral ischemia mouse model(With electric blanket to keep experimental animal rectal temperature at 37 ± 0.5 degree).The ABG-001 (0.5-1.0mg/kg) for proceeding by continuous 14 days for 48 hours after cerebral ischemia is injected intraperitoneally.Give within the 3rd day after cerebral ischemia BrdU injections.And irrigate fixed brain tissue through left ventricle with 4% paraformaldehyde in 28 days after cerebral ischemia, BrdU immunostainings are carried out, newborn neuron is marked.
Experimental result(Fig. 4):ABG-001 administrations can promote the survival and the migration to brain damage area corpus straitum of newborn neuron after cerebral ischemia, and be easy to recover the nervous function after ischemic brain damage.
Theoretically analysis and preliminary experimental result illustrate that other compounds in all embodiments 1 also have the effect similar to ABG-001.
The ABG-001 acute high doses of embodiment 3 are oral, Long-term Oral and intraperitoneal administration do not occur toxic reaction
Test main material:ICR mouse(Body weight 22g 25g, male and each 5 of female, purchased from Zhejiang University's Experimental Animal Center.
Experimental implementation:ABG-001 is relatively insoluble in water.(1) ABG-001 is dissolved in 99.5% ethanol, then adds 1%
Tween 80, with normal saline dilution to concentration(2%) ultimate density of ethanol is less than.Oral medication 5g/kg.(2) abdominal channels are administered, and ABG-001 is dissolved in into dimethyl sulfoxide(), DMSO then with normal saline dilution to concentration(DMSO ultimate densities are below 1%);
Acute poisoning test:By 4 week old ICR male mices 20, male and female half and half are randomly divided into control group, 5g/kg treatment groups.The compound ABG-001 for being dissolved in l%Tween-80 is orally taken medicine 5g/kg, the state of mind of Continuous Observation one week, daily observation animal determines body weight and food ration.There are Juan Shrink in mouse limb after compound is put into 10 minutes, and amount of exercise is reduced.After 1 hour, full recovery is normal.Mouse is without death condition in one week, and food ration is significantly reduced without significant change, but changes of weight.The heart, liver, spleen, kidney and white adipose tissue weight and observe that there was no significant difference.
Experimental result:
(1) table 2 is shown, compared with saline control group, and increased weight/reduction does not occur in ABG-001 treatment groups animal(Including each organ weights), also do not breathe(50 60 beats/min), heart rate(305 400 beats/min), mean arterial pressure(Exception 210mmHg), and the phenomenon such as lethargic sleep, manic, motor behavior exception.
Table 2:ICR mouse blood biochemical indicators(Every group early=10 ,=10;ABG-001=5g/kg gavages)
|
GLO
TP ALB ^
B ALT AST TBIL DBIL CHE
Group (g/L (g/L A/G
(g/L (U/L) (U/L) (umol/L) (umol/L) (U/L) ) )
)
56.86 40.20 16.66 2.42 31.00
It is early right
1.62 0.82 9350.80 Shi Shishishishi
Clear ± 0.34 ± 0.09 ± 156.32
0.43 0.37 0.32 0.06 2.28
57.54 39.00 18.54 2.12 33.40
Early 111.40 1.62 0.96 10075.40 Shi Shishishishi
5g/kg ± 15.80 ± 0.16 ± 0.08 ±411.98
1.24 1.30 0.98 0.14 1.44
57.40 36.50 20.90 1.75 37.75
Very little 88.75 1.48 0.87 6081.50 Shi Shishishishi
Clear ± 12.16 ± 0.33 ± 0.11 ± 184.27
2.11 0.86 1.33 0.09 2.49
54.68 18.68 1.94 32.00
75.40 1.64 0.91 5974.60 Shi Shishishi
5g/kg ±2.34 ± 0.27 ± 0.04 ± 153.90
In 0.88 0.24 0.07 1.10 tables 2, TP (total proteins), ALB (albumin), GLOB (globulin), ALT (ALTs), AST (glutamic-oxalacetic transamineases), TBIL (total bilirubins), DBIL (bilirubin directs), CHE (acetylcholinesterases)(2) compared with saline control group, exception of the ABG-001 5g/kg groups without display blood biochemical analysis index(Table 3), point out the functions such as liver, kidney, blood forming organ not to be compromised.
Table 3:ICR mouse weights and each organ coefficient(Every group 10 ,=5, early=5; ABG-001=5g/kg)
Group body weight(G) heart(%) liver(%) kidney(%) spleen(It is %) fatty(%)
24.64 0.685 2.102 0.684 3.185
Control group
±0.38 ±0.086 ±0.148 ±0.078 ±0.260
23.67 0.607 7.904 2.200 0.698 2.129
5g/kg group ± 0.86 ± 0.044 ± 0.289 ± 0.110 ± 0.036 ± 0.105
20.30 0.658 6.669 1.681 0.607 2.848 early control groups
± 0.56 ± 0.031 ± 0.205 ± 0.046 ± 0.038 ± 0.384 early 19.12 0.726 6.373 1.756 0.701 2.095
5g/kg group ± 1.41 ± 0.037 ± 0.234 ± 0.047 ± 0.039 ± 0.405 organ coefficient=internal organs weight/body weight(%)
Chronic toxicity test:ABG-001 carries out the intraperitoneal injection of continuous 60 days(10 mg/kg/ days), or oral administration(10 mg/kg/ days)(Saline administration is as a control group)Afterwards, body weight is detected.With 10% chloraldurate intraperitoneal anesthesia, recording respiration, heart rate and mean arterial pressure.Then the detection of blood progress hematology and blood biochemical analysis index etc. is taken from left ventricle.And take out the histological observation of each internal organs progress.
Experimental result:
(1) table 4 is shown, compared with saline control group, and increased weight/reduction does not occur in ABG-001 treatment groups animal(Including each organ weights).Also do not breathe(50 60 beats/min), heart rate(305 400 beats/min), mean arterial pressure(Exception 210mmHg), and the phenomenon such as lethargic sleep, manic, motor behavior exception.
Table 4:Mouse weight and each organ coefficient(Every group=10 ,=10;ABG-001=10mg/kg gavages)Group body weight(G) lung(%) heart(%) liver(%) kidney(%) spleen(%)
36.50 0.71 0.502 5.093 1.302 0.419 control groups
± 2.84 ± 0.21 ± 0.10 ± 0.32 ± 0.20 ± 0.12 solvent 33.20 0.82 0.605 5.128 1.235 0.405
(gavage)± 2.72 ± 0.24 ± 0.19 ± 0.43 ± 0.17 ± 0.09 solvent 36.22 0.78 0.524 4.912 1.193 0.368
(abdominal cavity) ± 2.47 ± 0.12 ± 0.16 ± 0.55 ± 0.18 ± 0.14
ABG-001
35.83 0.87 0.482 5.243 1.203 0.390 (gavages)
±2.11 ±0.28 ±0.22 ±0.67 ±0.32 ±0.07 lOmg/kg
ABG-001
32.30 0.80 0.523 5.031 1.133 0.371 (abdominal cavities)
± 3.42 ± 0.19 ± 0.15 ± 0.37 ± 0.15 ± 0.09 5mg/kg organ coefficients=internal organs weight/body weight
(2) compared with saline control group, chronic ABG-001 administration groups do not show blood biochemical analysis index(Table 5) exception, point out liver, kidney, the function such as blood forming organ not to be compromised.
Table 5:The biochemical index of mouse major blood(Every group=10 ,=10; ABG-001=:10mg/kg gavages)
GLO
TP ALB ALT TBIL DBIL
B AST CHE
Group (g/ (g/L A/G (U/L (umol (umol/L
(g/L (U/L) (U/L)
L) ) ) /L) )
)
57.2 38.5 17.7 32.2 85.4 7863.2
2.14 1.71
82952 0.71 4 control group ± 0.0 ± 0.2
±0.6 ±0.5 ±0.9 ±1.4 ±15. ±0.10 ±120.6
8 4
9 8 2 3 2 7
56.2 39.9 19.1 32.8 111. 8017.4
2.01 1.58
Solvent 3445 41 0.92 0
±0.0 ±0.1
(turn over) ±1.0 ±0.9 ±1.2 ±1.4 ±17. ±0.08 ±168.5
7 9
4 7 1 4 10 4
57.1 36.5 18.4 33.6 75.7 7684.3
1.91 1.63
Solvent 07318 0.85 8
±0.1 ±0.2
(abdominal cavity) ± 1.1 ± 0.6 ± 0.8 ± 1.9 ± 14. ± 0.09 ± 176.5
3 6
1 7 1 9 72 9
ABG-00 55.7 38.2 20.0 33.0 85.6 8344.7
2.04 1.70
1 (gavage) 8 5 2 4 3 0.91 5
±0.0 ±0.1
10mg/k ±0.6 ±1.0 ±1.0 ±1.0 ±11. ±0.05 ±191.8
8 9
g 0 2 4 3 41 3
56.8 37.4 18.3 32.1 89.4 7976.4
ABG-00 1.88 1.51
9 3 5 9 7 0.89 3
1 (abdominal cavity) ±0.0 ±0.3
±1.1 ±0.7 ±0.8 ±1.5 ±15. ±0.09 ±143.0
5mg/kg 9 5
In 7274 98 6 tables 5, TP (total proteins), ALB (albumin), GLOB (globulin), ALT (phenylalanine ammonia group-transfers
Enzyme), AST (glutamic-oxalacetic transamineases), TBIL (total bilirubins), DBIL (bilirubin directs), CHE (acetylcholinesterases).Theoretically analysis and preliminary experimental result illustrate that other compounds in all embodiments 1 also have the effect similar to ABG-001.The ABG-001 of embodiment 4 can pass through blood-brain barrier(Fig. 5)
Test main material:Sprague-Dawley (SD) rat(Male and each 10 of female), body weight 200g 250g, purchased from Jiangsu Province's Experimental Animal Center.
Experimental implementation:10% chloraldurate intraperitoneal anesthesia, record microelectrode according to after 0.3mm, foretells at 1.0mm sunset, the coordinates of 2.5 mm depth inserts CA1 pyramidal cell at hippocampus layer, the spontaneity discharge frequency of record hippocampus CA1 nerve cell.After basic value stable recording 20 minutes, ABG-001 carries out intraperitoneal administration, continuous record 1-2 hours.Analyze whether ABG-001 can adjust the excitability of hippocampal neurons through blood-brain barrier.
Experimental result(Fig. 5):ABG-001 (0.5-lmg/kg) is injected intraperitoneally 20-30 minutes afterwards, spontaneity discharge frequency, which occurs, in hippocampus CA1 nerve cell substantially to be increased, and continue more than 2 hours, point out ABG-001 that the excitability of nerve cell by blood-brain barrier, can be adjusted.
Theoretically analysis and preliminary experimental result illustrate that other compounds in all embodiments 1 also have the effect similar to ABG-001.Embodiment 5, ABG-001 can promote the regeneration of brain neuron by blood-brain barrier(Fig. 6)
In 1988, Erikssion etc. was marked with a division cells with BrdU (5-bromodeoxyuridine), finds the NSC of adult mammal hippocampus and can be divided into the nerve to occur of nerve cell one.The newborn neuron of adult hippocampal dentate fascia Neng Yu CA3 areas neuron similar to ripe granular cell sets up synaptic contact and occurs synaptic plasticity.The nerve to occur of adult can replace due to the neuronal death that natural aging or lesion are caused, and the integrality of brain function and structure is safeguarded to greatest extent.Research has shown that the neonatal cell member of old brain is reduced(Nerve regeneratl fails)It is relevant with Age-related cognitive hypofunction.This experiment primary part observation ABG-001 is to nerve to occur(Mainly include nerve stem cell proliferation, survival, differentiation)Effect.
Test main material:2 monthly age kunming mices(Male and each 40 of female), body weight 25g 30g, purchased from Jiangsu Province's Experimental Animal Center.
Experimental implementation:1. BrdU (5- bromodeoxyuridine nucleosides is used)The cell of m period is marked, ABG-001 administrations are carried out within continuous 14 days after B U injections(0.5mg/kg/d).Then 48 hour, days and 28 days methods with SABC detect that the BrdU in hippocampus DG areas is positive after BrdU first administrations respectively(BrdU+) cell, to determine ABG-001 cell proliferations(24 hour age-BrdU+Cell), survival(7 day age-BrdU+Cell)And maturation(28 day age-BrdU+Cell)Influence.2. neuronal specificity nucleoprotein is used() and Deiter's cells NeuN(GFAP immunostaining), influences of the observation ABG-001 to newborn Neural Differentiation.3. Doublecortin (DCX) immunostaining, influences of the observation ABG-001 to newborn neuron enation are used.ABG-001 is administered:ABG-001 is dissolved in 99.5% ethanol or dimethyl sulfoxide, is then injected intraperitoneally with tea oil dilution, or be administered orally with normal saline dilution.
Experimental result(Fig. 6):ABG-001 is oral or intraperitoneal administration can promote the propagation of hippocampal dentate NSC(A), the enation of newborn neuron is promoted(B), stem cell Differentiating Into Neurons are promoted(C), prompting ABG-001 has god
Through trophism.
Theoretically analysis and preliminary experimental result illustrate that other compounds in all embodiments 1 also have the effect similar to ABG-001.Embodiment 6, ABG-001 have the effect of Anti-endotoxin activity always(Fig. 7)
6-1:
Mammal obtains galactolipin from lactose, and lactose hydrolyzes generation glucose and galactolipin in vivo, and galactolipin is then digested into rapidly glucose in liver.Excessive galactolipin is reduced into galactitol under AR enzymatic.Galactitol is end product of metabolism, it is impossible to is further divided metabolism and accumulates, and increases the osmotic pressure of cell, causes cellular swelling, dysfunction and metabolic disorder, ultimately result in body aging.Substantial amounts of research report, D-gal galactolipins induction aged animal model.The D-gal retrogressions such as slow, projection comes off, the death rate increases that make rat embryo brain neuron occur growing.D-gal causes the fibroblastic external division algebraically of induced lung to reduce, and G2-M phases Leukopenia, the increase of G-G1 phases cell in diploid fibroblast division cycle, cell proliferation rate slow down.D-gal suppresses cell development and reduces division number of times, accelerates cell ageing.
Test main material:2 monthly age kunming mices(Male and each 30 of female), body weight 25g 30g, purchased from Jiangsu Province's Experimental Animal Center.
Experimental implementation:D-gal galactolipins(100mg/kg/ days)The intraperitoneal injection of progress 60 days.After 6 weeks, mouse is slow in action, and hair color is gloomy, and body is thin and weak, obvious aging sign is presented, it was demonstrated that aging model is successfully established.After D-gal galactolipins are injected 20 days, ABG-001 is proceeded by oral(0.1st, 5.0,10.0 mg/kg/ days)Or intraperitoneal injection(0.1st, 0.5,5 mg/kg/ days).When D-gal is injected 30 days, continuous 4 times of BrdU (5- bromodeoxyuridine nucleosides, 50.0 mg/kg) injections are given, are spaced 6 hours.Then respectively 28 days after BrdU administrations, fixed brain tissue is irrigated through left ventricle with 4% paraformaldehyde, BrdU immunostainings is carried out, marks newborn neuron.Detect that the BrdU in hippocampus DG areas is positive(BrdU+) cell, to determine that ABG-001 is survived and ripe to neonatal cell(28 day age-BrdU+Cell)Influence.With Doublecortin (DCX) immunostaining, influences of the observation ABG-001 to newborn neuron enation.Mouse was put to death in the 2nd day after last dose, hippocampus is taken out and cerebral cortex determines glutathione peroxidase (glutathione peroxidase, GSH2Px), superoxide dismutase(Superoxide dismutase, SOD), monoamine oxidase (monoamine oxidase, MAO) standing grain mouthful TAC(Total anti-oxidation competence, T-ACO) etc. aging biochemical indicator.
Experimental result(Fig. 7):(1) D-gal galactolipins long term injections can significantly reduce the quantity of newborn neuron, damage the enation of newborn neuron(a) ;(2) motor function of D-gal galactolipins-mouse aging is without obvious abnormal(B), but Spatial learning and memory function is substantially reduced;(3) ABG-001 treatments can improve survival and the enation obstacle of newborn neuron caused by D-gal(a) ;(4) ABG-001 treatments can improve the memory function of brain aging mouse(C) and(d) ;(5) the oxidative stress biochemical indicator of mouse(Every group early=10,3=10;ABG-001=10mg/kg gavages)Show that TAC improves unobvious(E), (f), (g) and(h) .Test main material:SAM R1 (6 week old male, each 18)With SAM P8 (9 week old male, each 18)It is purchased from affiliated hospital of Medical University Of Tianjin first.SAM P8 mouse are a kind of quick aging animal models.
Experimental implementation:SAM P8 September age mouse are randomized into 3 groups, control group(The physiological saline of 1% Tween 80), low dosage(Lmg/kg) group and high dose(3mg/kg) group, every group 6.Another sunset is foretold, the week old mouse of SAM R1 six as normal aging mouse young control.The physiological saline or ABG-001 of 1% Tween 80, continuous two weeks is injected intraperitoneally in each group daily.The detection of learning and memory and spatial memory function.(1) Y-maze is tested:Spontaneous alternative behavior can be assessed with Y-maze experiments.Y-maze is that black Y shape trisection radiant type is got lost case, is made up of 3 support arms and a bonding pad, three arms, 120 ° of angle with each other, it is upper wide 8 centimetres per 38.5 centimetres of brachium, it is lower wide 3.5 centimetres, it is high 12 centimetres, three arms can an optional arm be starting arm.Every mouse discharges from the end for fixing an arm, makes mouse freely movable 8 minutes, and record enters the order of arm every time.Continuously enter three different arm arms for three times and be decided to be and alternately enter arm(Such as:ABC, ACB, BAC, BCA, CAB, CBA).Alternately enter being calculated as arm rate:1 one(2) χ 100% of errors number/total degree 1.Enter arm number of times in addition, total and can also determine.(2) novelty distinguishes experiment:Novelty distinguishes that experiment is that the ability being familiar with novelty is distinguished according to rodent.Using to device be white uncovered box(The long wide X of X are high:18 centimetres of 40x20x).First, what object is not let alone in box, mouse is discharged from identical location point every time, allows adapt to environment, referred to as laundering period, totally two days within its free movable 5 minutes.It is within 3rd day to be familiar with phase and test phase.It is familiar with the phase:First it is put into after two same objects, mouse is put into, freely activity 5 minutes, be less than 2 centimetres away from object with mouse nose or lie prone worthwhile for exploratory behavior in identified object, records respectively and the time is probed into two same objects.The test phase:Two different objects are changed in interval after 1 hour(One of them is and is familiar with phase identical object(0, another is novelty (n)), allow its freely activity 5 minute, and record mouse probing into time f and time n is probed into novelty to familiar objects.It is familiar with phase and test phase to put by random digit two kinds of objects of combination and position.The calculation formula of cognitive index be the time n/ that probes into novelty always probe into time n+f.
Experimental result(Fig. 8):(1) compared with SAM R1 mouse, always entering arm number of times and alternately entering arm rate for SAM P8 mouse does not substantially change(a);(2) receive high dose or low dosage ABG-001 processing SAM P8 mouse compared with the SAM R1 mouse and SAM P8 mouse do not treated learning and memory function be remarkably reinforced(b);(3) compared with SAM R1 mouse, SAM P8 mouse substantially reduce to the resolving ability of novelty(c);(4) ABG-001 processing energy concentration dependent recovers resolving ability of the SAM P8 mouse to novelty(d).
Theoretically analysis and preliminary experimental result illustrate that other compounds in all embodiments 1 also have the effect similar to ABG-001.Embodiment 7, ABG-001 have the effect of prevention and treatment senile dementia(Fig. 9)
74
Test main material:Sprague-Dawley (SD) rat(Male and each 20 of female), body weight 200g 250g, purchased from Jiangsu Province's Experimental Animal Center.1. stereotaxic technique is used, by osmotic pump (osmotic minipump: Alzet 2002;Alze, CA) connection implantation catheter(Cannula), and be fixed on one side telocoele (0.3mm, right side lmm, deep 2.5mm after bregma).By Α β( 1_ 42) continuous 2 weeks(100pM/day) it is fed into telocoele.By observing Α β deposition, spatial memory function and Cholinergic, to verify whether AD models succeed.
Experimental implementation: Αβ( 1_ 42) irrigate after proceed by within the 2nd day continuous 14 days ABG-001 (0.5-1.0mg/kg) intraperitoneal injection.In Α β α -42 )Carry out water maze test within the 7th day after perfusion, check spatial memory function.The movement locus of rat is recorded, calculating is gone up on the stage incubation period.In Α βα_42)15 days after perfusion, fixed brain tissue is irrigated through left ventricle with 4% paraformaldehyde.
After FFPE, hippocampus serial section is done.After 1% Toluidine blue staining, the density of measurement hippocampus CA1 area survival cones (pyramidal cell layer per mm length in granular cell number).
Experimental result Fig. 9: Αβα_42)Perfusion causes about 60% hippocampus CA1 area neuronal death to be lost, and causes escape latency to extend, and points out the reduction of spatial cognition function.ABG-001 treatments can significantly reduce Α βα_42)Dementia rats hippocampal neurons are dead, improve the Spatial memory function of Α β rats.
ABG-001 treatments can improve the brain endogenous nerve regneration obstacle of Alzheimer disease (AD)
The NSC of Adult Mammals hippocampal dentate can be divided into nerve cell referred to as nerve to occur.The nerve to occur of adult is considered to replace and repaired due to the neuron loss that natural aging or lesion are caused, and the 26S Proteasome Structure and Function of brain is safeguarded to greatest extent.Alzheimer disease (Alzheimer's disease, AD) is a kind of nervous system degenerative disease being characterized with progressive cognition dysfunction.Whether newborn neuron can substitute the neuron of lesion, improve AD cognition dysfunction and turned into the novel targets that AD is studied.Research finds that the neuronotropic differentiation ratio of precursor of AD cerebral hippocampals is significantly reduced, and the survival rate of synkaingenesis neuron is significantly reduced, and the enation of newborn neuron is abnormal.These researchs have confirmed that the nerve regeneration of AD brains is by serious infringement, and it is probably one of important pathomechanism of AD cognitive functions progressive decline to point out nerve regneration obstacle.
Test main material:APP/PS1 transgenosis AD mouse(10 monthly age male and female mouse)(It is purchased from Nanjing University's zootype center).Experimental implementation:With BrdU (5- bromodeoxyuridine nucleosides)The cell of m period is marked, ABG-001 administrations are carried out within continuous 14 days after B U injections(0.5mg/kg/ days).Then 28 days methods with SABC detect that the BrdU in hippocampus DG areas is positive after BrdU first administrations respectively(BrdU+) cell.Pass through neuronal specificity nucleoprotein() and Deiter's cells NeuN(GFAP immunostaining), influences of the observation ABG-001 to newborn Neural Differentiation.Doublecortin (DCX) in the growth course of central nervous system neural precursor transition process particular expression, DCX as neuronal precursor mark can for study neuronal precursor propagation and migration.The growth of newborn Neuronal processes can be observed by being dyed by DCX.Mouse was put to death in the 2nd day after last dose, hippocampus is taken out and determines acetylcholinesterase(AChE it is) active.
Experimental result(Figure 10):Compared with wild-type mice, 28 day age-BrdU+ cell of APP/PS1 adult mouse dentate gyrus shows 50% reduction(a);Newborn neuron number of projection and length are significantly reduced(b).ABG-001 treatments can improve APP/PS1 mouse 28 day age-B U+ cells and substantially reduce(A) growth of nervous process, is protected(B), prompting ABG-001 has the effect for improving AD neurogenesis and cognition dysfunction.The acetylcholinesterase of APP/PS Hippocampus of Mice(AChE) activity has slight increase, and ABG-001 treatments can substantially lower AD hippocampus of mice acetylcholinesterases(AChE it is) active (c).
Theoretically analysis and preliminary experimental result illustrate that other compounds in all embodiments 1 also have the effect similar to ABG-001.The preparation method of embodiment 8, ABG-001 tablets
Prescription:
ABG-001 100g
Starch 40g
Microcrystalline cellulose 80g
Magnesium stearate 3.0g
Hydroxypropyl methyl cellulose(E-30) (40% solution)In right amount
It is made 1000
Preparation method:4% is prepared through propyl methocel(E-30) solution, it is standby.Weighing 10g starch, to put 105 °C of dryings 5 hours standby.Weigh 20 g starch and recipe quantity invents ABG-001, microcrystalline cellulose, and 80 mesh sieves were crushed in mixing.With 4% through propyl methocel(E-30) solution pelletizes material softwood, in the % of moisture content 3 of 50 °C of 60 °C of dryings into particle or so with 20 mesh sieves.20 mesh sieve whole grains are crossed, the dried starch of recipe quantity is added(105 °C of dryings 5 hours), magnesium stearate, it is mixed eventually, survey intermediates content, stator weight;Tabletting.
The preparation method of embodiment 9, ABG-001 parenteral solutions
Prescription:
ABG-001 10g
Propane diols 500mL
Water for injection 500mL
LOOOmL is made
Preparation method:Weigh the ABG-001 and propane diols of recipe quantity, plus the mL of water for injection 500, stirring and dissolving;0.1 % activated carbons are added into above-mentioned solution, are stirred, are placed 15 minutes, 5 microns of titanium rods take off charcoal, then the miillpore filter refined filtration through 45 microns of 0, of filter cartridge and 22 microns of 0,;Embedding is in 10 ml ampoule bottles, and 100 °C of flowing steams sterilize 45 minutes, produce invented ABG-001 parenteral solution.
Claims (1)
- Claims1st, the application of a kind of benzoic ether and its derivative in the medicine for preparing prevention and treatment nerve degenerative diseases, it is characterised in that the benzoic acid following structure formula:Wherein, R is carbon number from 1 to 30 straight chain, side chain, saturation and unsaturated protective embankment base, cycloaliphatic ring or their derivative;Separately it is selected from hydrogen, hydroxyl, carboxyl, aldehyde radical, ester group, fluorine, chlorine, bromine, iodine, sulfydryl, amino, amide groups, cyano group, nitro, sulfonic group, trifluoromethyl, acrylic, protective embankment base, protective embankment epoxide, substituted benzyl, substituted-phenyl, aryl, heteroaryl, glycosyl or amino acid residue;X is selected from C (0) 0, OC (0), C (0) NH, NHC (0), C (0), CH2, S or 0.2nd, application according to claim 1, it is characterised in that the R is carbon number from 6 to 22 straight chain, side chain, saturation and unsaturated protective embankment base, cycloaliphatic ring or their derivative.3rd, application according to claim 1, it is characterised in that the benzoic ether and its derivative are: 2,3- dihydric ethyl benzoates, 2,3- dihydroxy-benzoic acid pentyl esters, 2,3- dihydroxy-benzoic acid monooctyl esters, 2,3- dihydroxy-benzoic acid last of the ten Heavenly stems esters, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 12, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 14, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 16, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 18, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 20, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 22, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 30, 2,The protective embankment ester of 6- dihydroxy-benzoic acids 14, 2,The protective embankment ester of 6- dihydroxy-benzoic acids 20, 2,The protective embankment ester of 4- dihydroxy-benzoic acids 14, 3,The protective embankment ester of 4- dihydroxy-benzoic acids 14, 3, 4,The protective embankment ester of 5- trihydroxybenzoic acids 14,The protective embankment ester of 2 hydroxybenzoic acid 14,The protective embankment ester of 3- hydroxybenzoic acids 14, 2,The protective embankment ester of 3- dimethoxybenzoic acids 14, 2,The protective embankment ester of 3- dimethoxybenzoic acids 18,The protective embankment ester of 2- hydroxy 3-methoxybenzenes formic acid 14,The protective embankment ester of 2- chlorobenzoic acids 14, 2,The protective embankment yl-benzamides of 3- dihydroxy-N- 14, 2,3- dihydroxy-N- octyl group benzamides, 2,The protective embankment yl-benzamides of 3- dihydroxy-N- 12, 2,The protective embankment yl-benzamides of 3- dihydroxy-N- 16, 2,The protective embankment yl-benzamides of 3- dihydroxy-N- 18, 2,The protective embankment yl-benzamides of 3- dimethoxys-N- 14, 3,The protective embankment yl-benzamides of 4- dihydroxy ^- 14, 3, 4,The protective embankment yl-benzamides of 5- trihydroxies-N- 14, N- (3,4- Dimethoxyphenyls) 14 (protective embankment) acid amides, N- (3,4- dihydroxyphenyls) 14 (protective embankment) acid amides, 1- (3,4- Dimethoxyphenyls) 14 protective embankment -1- ketone, 1- (3,4- dihydroxyphenyls) 14 protective embankment -1- ketone,3- (14 protective embankment Epoxide carbonyl) -1,2- phenyl diacetates,3- (14 protective embankment base formoxyl) -1,2- phenyl diacetates,5- (14 protective embankment Epoxide carbonyls)Benzene -1,2,3- triacetates, 5- (14 protective embankment base formoxyls)Benzene -1,2,3- triacetates, 1,2- phenylene 20 Acid esters, 2,3- dihydroxyphenyls 14 (protective embankment) hydrochlorate, 3- (14 protective embankment oxygen) benzene -1,2- glycol.4th, the application of a kind of benzoic ether and its derivative in prevention and the old medicine for the treatment of Anti-endotoxin activity is prepared, it is characterised in that the benzoic ether and its derivative have following structure formula:Wherein, R is carbon number from 1 to 30 straight chain, side chain, saturation and unsaturated protective embankment base, cycloaliphatic ring or their derivative;Separately it is selected from hydrogen, hydroxyl, carboxyl, aldehyde radical, ester group, fluorine, chlorine, bromine, iodine, sulfydryl, amino, amide groups, cyano group, nitro, sulfonic group, trifluoromethyl, acrylic, protective embankment base, protective embankment epoxide, substituted benzyl, substituted-phenyl, aryl, heteroaryl, glycosyl or amino acid residue;X is selected from C (0) 0, OC (0), C (0) NH, NHC (0), C (0), CH2, S or 0.5th, application according to claim 4, it is characterised in that the R is carbon number from 6 to 22 straight chain, side chain, saturation and unsaturated protective embankment base, cycloaliphatic ring or their derivative.6th, application according to claim 4, it is characterised in that the benzoic ether and its derivative are: 2,3- dihydric ethyl benzoates, 2,3- dihydroxy-benzoic acid pentyl esters, 2,3- dihydroxy-benzoic acid monooctyl esters, 2,3- dihydroxy-benzoic acid last of the ten Heavenly stems esters, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 12, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 14, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 16, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 18, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 20, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 22, 2,The protective embankment ester of 3- dihydroxy-benzoic acids 30, 2,The protective embankment ester of 6- dihydroxy-benzoic acids 14, 2,The protective embankment ester of 6- dihydroxy-benzoic acids 20, 2,The protective embankment ester of 4- dihydroxy-benzoic acids 14, 3,The protective embankment ester of 4- dihydroxy-benzoic acids 14, 3, 4,The protective embankment ester of 5- trihydroxybenzoic acids 14,The protective embankment ester of 2 hydroxybenzoic acid 14,The protective embankment ester of 3- hydroxybenzoic acids 14, 2,The protective embankment ester of 3- dimethoxybenzoic acids 14, 2,The protective embankment ester of 3- dimethoxybenzoic acids 18,The protective embankment ester of 2- hydroxy 3-methoxybenzenes formic acid 14,The protective embankment ester of 2- chlorobenzoic acids 14, 2,The protective embankment yl-benzamides of 3- dihydroxy-N- 14, 2,3- dihydroxy-N- octyl group benzamides, 2,The protective embankment yl-benzamides of 3- dihydroxy-N- 12, 2,The protective embankment yl-benzamides of 3- dihydroxy-N- 16, 2,The protective embankment yl-benzamides of 3- dihydroxy-N- 18, 2,The protective embankment yl-benzamides of 3- dimethoxys-N- 14, 3,The protective embankment yl-benzamides of 4- dihydroxy ^- 14, 3, 4,The protective embankment yl-benzamides of 5- trihydroxies-N- 14, N- (3,4- Dimethoxyphenyls) 14 (protective embankment) acid amides, N- (3,4- dihydroxyphenyls) 14 (protective embankment) acid amides, 1- (3,4- Dimethoxyphenyls) 14 protective embankment -1- ketone, 1- (3,4- dihydroxyphenyls) 14 protective embankment -1- ketone,3- (14 protective embankment Epoxide carbonyl) -1,2- phenyl diacetates,3- (14 protective embankment base formoxyl) -1,2- phenyl diacetates,5- (14 protective embankment Epoxide carbonyls)Benzene -1,2,3- triacetates, 5- (14 protective embankment base formoxyls)Benzene -1,2,3- triacetates, the acid esters of 1,2- phenylene 20,2,3- dihydroxyphenyls 14 (protective embankment) hydrochlorate, 3- (14 protective embankment oxygen) benzene -1,2- glycol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010103089.6A CN101817761B (en) | 2010-01-29 | 2010-01-29 | Benzoate derivatives, preparation method and application |
PCT/CN2010/079918 WO2011091692A1 (en) | 2010-01-29 | 2010-12-17 | Uses of benzoate and its derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103118677A true CN103118677A (en) | 2013-05-22 |
Family
ID=42653061
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010103089.6A Active CN101817761B (en) | 2010-01-29 | 2010-01-29 | Benzoate derivatives, preparation method and application |
CN2010800626231A Pending CN103118677A (en) | 2010-01-29 | 2010-12-17 | Uses of benzoate and its derivatives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010103089.6A Active CN101817761B (en) | 2010-01-29 | 2010-01-29 | Benzoate derivatives, preparation method and application |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN101817761B (en) |
WO (1) | WO2011091692A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101817761B (en) * | 2010-01-29 | 2014-06-25 | 浙江大学 | Benzoate derivatives, preparation method and application |
CN103340880B (en) * | 2013-05-13 | 2014-12-24 | 杭州耐奇睿生物医药科技有限公司 | Application of 2,3-dihydroxy benzoic acid ester compound in preparation of foods and medicines for treating diabetes |
CN105085348B (en) * | 2014-05-20 | 2017-07-25 | 浙江大学 | A kind of benzoic acid sulfur ester and its application |
CN106608824B (en) * | 2015-10-21 | 2019-12-20 | 复旦大学 | Aromatic acid ester compound and preparation method and application thereof |
CN108553456B (en) * | 2016-12-29 | 2020-09-15 | 天津中医药大学 | Use of benzoic acid and derivatives thereof |
CN109422858A (en) * | 2017-08-19 | 2019-03-05 | 中国铁道科学研究院铁道建筑研究所 | A kind of polyalcohol being grafted UV absorption agent molecule |
CN114292192A (en) * | 2022-01-17 | 2022-04-08 | 山东泓瑞医药科技股份公司 | Synthesis method of 3, 4-dimethoxybenzoic acid methyl ester |
CN114956971A (en) * | 2022-05-24 | 2022-08-30 | 浙江禾本科技股份有限公司 | Method for preparing miticide intermediate 2-lauroyl-1-naphthol and analogue thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3729563A (en) * | 1970-12-08 | 1973-04-24 | Ciba Geigy Corp | Method of treating movement disorders |
CN101817761A (en) * | 2010-01-29 | 2010-09-01 | 浙江大学 | Benzoate derivatives, preparation method and application |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
IL117629A (en) * | 1995-04-03 | 2000-08-13 | Centaur Pharmaceuticals Inc | Pharmaceutical compositions containing a benzamide derivative and methods for the preparation thereof |
ITMI962356A1 (en) * | 1996-11-13 | 1998-05-13 | Uni Degli Studi Di Brescia D I | USE OF COMPOUNDS DERIVED FROM MOLECULES WITH NON-STEROID ANTI-INFLAMMATORY ACTIVITY FOR THE PREVENTION AND TREATMENT OF |
EP1603858A2 (en) * | 2003-03-11 | 2005-12-14 | NeuroSearch A/S | Kcnq channel modulating compounds and their pharmaceutical use |
US9526707B2 (en) * | 2007-08-13 | 2016-12-27 | Howard L. Elford | Methods for treating or preventing neuroinflammation or autoimmune diseases |
EP2305633B1 (en) * | 2008-07-04 | 2013-03-20 | Kissei Pharmaceutical Co., Ltd. | Catechol derivative and its use |
-
2010
- 2010-01-29 CN CN201010103089.6A patent/CN101817761B/en active Active
- 2010-12-17 CN CN2010800626231A patent/CN103118677A/en active Pending
- 2010-12-17 WO PCT/CN2010/079918 patent/WO2011091692A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3729563A (en) * | 1970-12-08 | 1973-04-24 | Ciba Geigy Corp | Method of treating movement disorders |
CN101817761A (en) * | 2010-01-29 | 2010-09-01 | 浙江大学 | Benzoate derivatives, preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
CN101817761B (en) | 2014-06-25 |
CN101817761A (en) | 2010-09-01 |
WO2011091692A1 (en) | 2011-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103118677A (en) | Uses of benzoate and its derivatives | |
CN100534992C (en) | Silybin esters derivatives and preparation and use thereof | |
US10322135B2 (en) | Pharmaceutical composition comprising indole compound | |
CN100596299C (en) | Dehydrosilibinin diester derivatives, preparation method and use thereof | |
CN102146054A (en) | Piperlongumine derivatives and medicinal composition and application to preparation of medicament for inhibiting tumor growth thereof | |
CN103420942B (en) | Second, butyrylcholine esterase had dual restraining activities compound | |
CN103193789A (en) | Optically active butylphthalide open-ring derivative, preparation method and medical application | |
KR20210097100A (en) | 2-(1-acyloxy-n-pentyl)benzoic acid and a salt formed by a basic amino acid or aminoguanidine, preparation method and use thereof | |
TWI377064B (en) | Compounds from mycelium of antrodia cinnamomea and use thereof | |
CN107488162A (en) | A kind of bicyclic alcohol derivatives and its preparation and application | |
CN109988201B (en) | Glycoside compound, preparation method, composition, application and intermediate thereof | |
CN107963987B (en) | A stachydrine derivative, its preparation method and application in preparing medicine for treating cardiovascular disease and cerebrovascular disease | |
KR101659596B1 (en) | Derivative of butylphthalide and preparation method and use thereof | |
WO2022237913A1 (en) | Limonin compound, preparation method therefor, and application of limonin compound as drug for treating hydatidosis/echinococcosis | |
CN110483367A (en) | The purposes of Benzazole compounds in medicine preparation | |
CN102188477B (en) | Preparation method and application of active component of radix gentianae extractive | |
US9636324B2 (en) | Use of 15-benzylidence-14-deoxy-11, 12 -dehyroandrographolide derivative in manufacture of medicaments for protecting liver and anti-hepatitis C virus | |
CN112047910B (en) | Aromatic farnesyl compound and application thereof | |
WO2018068696A1 (en) | Pegylated sinomenine and derivative thereof and preparation method and use of same | |
EP3750904A1 (en) | Therapeutic drug for neurodegenerative disease and application thereof | |
CN115073463B (en) | Matrine type dimer alkaloid compound, pharmaceutical composition and application thereof | |
CN107141266B (en) | A kind of heterocyclic compound and preparation method thereof for treating Alzheimer disease | |
CN109956952B (en) | Alpha-toosedarin derivative and preparation method and application thereof | |
KR101629558B1 (en) | A Naphthochalcone and use of the same as anticancer drug | |
CN108261414B (en) | A kind of pharmaceutical composition for treating lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130522 |